

Piotr Ponikowski

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/4019717/publications.pdf](https://exaly.com/author-pdf/4019717/publications.pdf)

Version: 2024-02-01

746
papers

198,462
citations

179

149
h-index

24

427
g-index

796
all docs

796
docs citations

796
times ranked

119416
citing authors

#	ARTICLE	IF	CITATIONS
1	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2016, 37, 2129-2200.	2.3	13,423
2	2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 2018, 39, 119-177.	2.3	7,452
3	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 2021, 42, 3599-3726.	2.3	6,641
4	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Heart Journal, 2016, 37, 2893-2962.	2.3	5,796
5	2013 ESH/ESC Guidelines for the management of arterial hypertension. European Heart Journal, 2013, 34, 2159-2219.	2.3	5,742
6	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Journal of Heart Failure, 2016, 18, 891-975.	7.5	5,411
7	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal, 2012, 33, 1787-1847.	2.3	5,298
8	2017 ESC/EACTS Guidelines for the management of valvular heart disease. European Heart Journal, 2017, 38, 2739-2791.	2.3	5,257
9	2018 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 2019, 40, 87-165.	2.3	4,856
10	2007 Guidelines for the Management of Arterial Hypertension. Journal of Hypertension, 2007, 25, 1105-1187.	0.5	4,825
11	Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European Heart Journal, 2010, 31, 2369-2429.	2.3	4,682
12	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine, 2019, 381, 1995-2008.	30.1	4,502
13	2014 ESC/EACTS Guidelines on myocardial revascularization. European Heart Journal, 2014, 35, 2541-2619.	2.3	4,200
14	2013 ESC guidelines on the management of stable coronary artery disease. European Heart Journal, 2013, 34, 2949-3003.	2.3	3,973
15	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace, 2016, 18, 1609-1678.	1.6	3,645
16	2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. European Heart Journal, 2014, 35, 2733-2779.	2.3	3,623
17	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. European Heart Journal, 2012, 33, 2719-2747.	2.3	3,172
18	Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine, 2020, 383, 1413-1424.	30.1	3,134

#	ARTICLE	IF	CITATIONS
19	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). European Heart Journal, 2008, 29, 2388-2442.	2.3	2,677
20	2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. European Heart Journal, 2014, 35, 3033-3080.	2.3	2,642
21	Empagliflozin in Heart Failure with a Preserved Ejection Fraction. New England Journal of Medicine, 2021, 385, 1451-1461.	30.1	2,520
22	2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). European Heart Journal, 2018, 39, 763-816.	2.3	2,494
23	2012 focused update of the ESC Guidelines for the management of atrial fibrillation. Europace, 2012, 14, 1385-1413.	1.6	2,347
24	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. European Journal of Heart Failure, 2012, 14, 803-869.	7.5	2,327
25	2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. European Heart Journal, 2013, 34, 2281-2329.	2.3	2,209
26	2014 ESC/EACTS Guidelines on myocardial revascularization. European Journal of Cardio-thoracic Surgery, 2014, 46, 517-592.	1.4	2,192
27	Cachexia: A new definition. Clinical Nutrition, 2008, 27, 793-799.	5.1	1,970
28	ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. European Journal of Heart Failure, 2008, 10, 933-989.	7.5	1,904
29	2015 ESC Guidelines for the diagnosis and management of pericardial diseases. European Heart Journal, 2015, 36, 2921-2964.	2.3	1,876
30	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal, 2013, 34, 3035-3087.	2.3	1,791
31	Ferric Carboxymaltose in Patients with Heart Failure and Iron Deficiency. New England Journal of Medicine, 2009, 361, 2436-2448.	30.1	1,699
32	2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal, 2006, 28, 1462-1536.	2.3	1,629
33	2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. European Heart Journal, 2018, 39, 3165-3241.	2.3	1,538
34	Guidelines for the management of atrial fibrillation. Europace, 2010, 12, 1360-1420.	1.6	1,365
35	2018 ESC Guidelines for the diagnosis and management of syncope. European Heart Journal, 2018, 39, 1883-1948.	2.3	1,285
36	Wasting as independent risk factor for mortality in chronic heart failure. Lancet, The, 1997, 349, 1050-1053.	12.1	1,230

#	ARTICLE	IF	CITATIONS
37	Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. <i>New England Journal of Medicine</i> , 2021, 384, 117-128.	30.1	1,212
38	EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. <i>European Heart Journal</i> , 2006, 27, 2725-2736.	2.3	1,092
39	How to diagnose heart failure with preserved ejection fraction: the HFAâ€PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2019, 40, 3297-3317.	2.3	1,075
40	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 4-131.	7.5	1,057
41	Heart failure: preventing disease and death worldwide. <i>ESC Heart Failure</i> , 2014, 1, 4-25.	3.1	1,044
42	2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. <i>European Journal of Heart Failure</i> , 2017, 19, 9-42.	7.5	978
43	Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. <i>European Heart Journal</i> , 2015, 36, 657-668.	2.3	947
44	Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction. <i>New England Journal of Medicine</i> , 2020, 382, 1883-1893.	30.1	844
45	Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. <i>Lancet</i> , 2013, 381, 29-39.	12.1	824
46	Cardio-renal syndromes: report from the consensus conference of the Acute Dialysis Quality Initiative. <i>European Heart Journal</i> , 2010, 31, 703-711.	2.3	820
47	2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 50, e1-e88.	1.4	778
48	Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. <i>European Journal of Heart Failure</i> , 2021, 23, 352-380.	7.5	749
49	Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. <i>European Heart Journal</i> , 2009, 30, 2769-2812.	2.3	741
50	2016 European Guidelines on cardiovascular disease prevention in clinical practice. <i>European Journal of Preventive Cardiology</i> , 2016, 23, NP1-NP96.	1.8	707
51	Hormonal Changes and Catabolic/Anabolic Imbalance in Chronic Heart Failure and Their Importance for Cardiac Cachexia. <i>Circulation</i> , 1997, 96, 526-534.	9.3	678
52	EUR<i>Observational</i> Research Programme: regional differences and 1â€year followâ€up results of the Heart Failure Pilot Survey (ESCâ€HF Pilot). <i>European Journal of Heart Failure</i> , 2013, 15, 808-817.	7.5	667
53	Nutritional Recommendations for the Management of Sarcopenia. <i>Journal of the American Medical Directors Association</i> , 2010, 11, 391-396.	2.6	563
54	Iron deficiency in chronic heart failure: An international pooled analysis. <i>American Heart Journal</i> , 2013, 165, 575-582.e3.	3.1	560

#	ARTICLE	IF	CITATIONS
55	Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-term Registry. <i>European Journal of Heart Failure</i> , 2013, 15, 1173-1184.	7.5	549
56	Uric Acid and Survival in Chronic Heart Failure. <i>Circulation</i> , 2003, 107, 1991-1997.	9.3	543
57	Iron deficiency: an ominous sign in patients with systolic chronic heart failure. <i>European Heart Journal</i> , 2010, 31, 1872-1880.	2.3	538
58	2017 ESC/EACTS Guidelines for the management of valvular heart disease. <i>European Journal of Cardio-thoracic Surgery</i> , 2017, 52, 616-664.	1.4	527
59	Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. <i>New England Journal of Medicine</i> , 2017, 376, 1527-1539.	30.1	522
60	Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm. <i>New England Journal of Medicine</i> , 2012, 366, 1859-1869.	30.1	521
61	Clinical Correlates and Prognostic Significance of the Ventilatory Response to Exercise in Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 1997, 29, 1585-1590.	5.6	509
62	Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019, 21, 1169-1186.	7.5	506
63	Effect of Intravenous Iron Sucrose on Exercise Tolerance in Anemic and Nonanemic Patients With Symptomatic Chronic Heart Failure and Iron Deficiency. <i>Journal of the American College of Cardiology</i> , 2008, 51, 103-112.	5.6	498
64	Rolofylline, an Adenosine A ₁ Receptor Antagonist, in Acute Heart Failure. <i>New England Journal of Medicine</i> , 2010, 363, 1419-1428.	30.1	479
65	Mid-Region Pro-Hormone Markers for Diagnosis and Prognosis in Acute Dyspnea. <i>Journal of the American College of Cardiology</i> , 2010, 55, 2062-2076.	5.6	472
66	Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial. <i>Lancet</i> , 2020, 396, 1895-1904.	12.1	462
67	Palliative care in heart failure: a position statement from the palliative care workshop of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2009, 11, 433-443.	7.5	454
68	Depressed Heart Rate Variability as an Independent Predictor of Death in Chronic Congestive Heart Failure Secondary to Ischemic or Idiopathic Dilated Cardiomyopathy. <i>American Journal of Cardiology</i> , 1997, 79, 1645-1650.	1.6	438
69	Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. <i>European Heart Journal</i> , 2013, 34, 2453-2463.	2.3	438
70	Universal Definition and Classification of Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 387-413.	1.7	435
71	The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. <i>Nature Medicine</i> , 2022, 28, 568-574.	30.1	430
72	2010 Focused Update of ESC Guidelines on device therapy in heart failure: An update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. <i>European Heart Journal</i> , 2010, 31, 2677-2687.	2.3	429

#	ARTICLE	IF	CITATIONS
73	2018 ESC/EACTS Guidelines on myocardial revascularization. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 55, 4-90.	1.4	420
74	Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. <i>New England Journal of Medicine</i> , 2021, 384, 105-116.	30.1	413
75	Prognostic Utility of Growth Differentiation Factor-15 in Patients With Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1054-1060.	5.6	410
76	Effect of Serelaxin on Cardiac, Renal, and Hepatic Biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) Development Program. <i>Journal of the American College of Cardiology</i> , 2013, 61, 196-206.	5.6	404
77	Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. <i>Lancet</i> , The, 2009, 373, 1429-1439.	12.1	391
78	Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. <i>European Heart Journal</i> , 2020, 41, 1810-1817.	2.3	391
79	Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. <i>Lancet</i> , The, 2016, 387, 1178-1186.	12.1	386
80	Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 1353.	7.0	362
81	Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2011, 13, 1-10.	7.5	355
82	Anabolic Deficiency in Men With Chronic Heart Failure. <i>Circulation</i> , 2006, 114, 1829-1837.	9.3	351
83	EUR ² Observational Research Programme: The Heart Failure Pilot Survey (ESC-HF Pilot). <i>European Journal of Heart Failure</i> , 2010, 12, 1076-1084.	7.5	349
84	Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2007, 9, 684-694.	7.5	339
85	Effects of ferric carboxymaltose on hospitalisations and mortality rates in iron-deficient heart failure patients: an individual patient data meta-analysis. <i>European Journal of Heart Failure</i> , 2018, 20, 125-133.	7.5	331
86	Recommendations on pre-hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. <i>European Journal of Heart Failure</i> , 2015, 17, 544-558.	7.5	324
87	Iron deficiency and heart failure: diagnostic dilemmas and therapeutic perspectives. <i>European Heart Journal</i> , 2013, 34, 816-829.	2.3	317
88	Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency. <i>Circulation</i> , 2017, 136, 1374-1383.	9.3	311
89	Effect on Survival and Hospitalization of Initiating Treatment for Chronic Heart Failure With Bisoprolol Followed by Enalapril, as Compared With the Opposite Sequence. <i>Circulation</i> , 2005, 112, 2426-2435.	9.3	308
90	Effect of Vericiguat, a Soluble Guanylate Cyclase Stimulator, on Natriuretic Peptide Levels in Patients With Worsening Chronic Heart Failure and Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 2251.	7.0	304

#	ARTICLE	IF	CITATIONS
91	2010 Focused Update of ESC Guidelines on device therapy in heart failure. <i>Europace</i> , 2010, 12, 1526-1536.	1.6	298
92	A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). <i>European Journal of Heart Failure</i> , 2019, 21, 665-675.	7.5	298
93	Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOLuble guanylate Cyclase stimulator in heart failure patients with PRESERVED EF (SOCRATES-PRESERVED) study. <i>European Heart Journal</i> , 2017, 38, 1119-1127.	2.3	297
94	A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease. <i>European Heart Journal</i> , 2016, 37, 2105-2114.	2.3	293
95	Efficacy of the If current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. <i>European Heart Journal</i> , 2009, 30, 540-548.	2.3	289
96	Diuretic response in acute heart failure: clinical characteristics and prognostic significance. <i>European Heart Journal</i> , 2014, 35, 1284-1293.	2.3	287
97	Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials. <i>European Journal of Heart Failure</i> , 2016, 18, 786-795.	7.5	287
98	Distribution and Risk Profile of Paroxysmal, Persistent, and Permanent Atrial Fibrillation in Routine Clinical Practice. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2012, 5, 632-639.	5.0	272
99	Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. <i>European Journal of Anaesthesiology</i> , 2010, 27, 92-137.	1.8	267
100	Effect of Ularitide on Cardiovascular Mortality in Acute Heart Failure. <i>New England Journal of Medicine</i> , 2017, 376, 1956-1964.	30.1	263
101	Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation</i> , 2020, 141, 90-99.	9.3	259
102	Impaired Insulin Sensitivity as an Independent Risk Factor for Mortality in Patients With Stable Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2005, 46, 1019-1026.	5.6	256
103	Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. <i>European Journal of Heart Failure</i> , 2019, 21, 827-843.	7.5	256
104	Contemporary management of octogenarians hospitalized for heart failure in Europe: Euro Heart Failure Survey II. <i>European Heart Journal</i> , 2008, 30, 478-486.	2.3	254
105	Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. <i>Lancet</i> , 2016, 388, 2895-2903.	12.1	241
106	Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status. <i>Circulation</i> , 2021, 143, 337-349.	9.3	240
107	Improving care for patients with acute heart failure: before, during and after hospitalization. <i>ESC Heart Failure</i> , 2014, 1, 110-145.	3.1	235
108	Iron Deficiency Predicts Impaired Exercise Capacity in Patients With Systolic Chronic Heart Failure. <i>Journal of Cardiac Failure</i> , 2011, 17, 899-906.	1.7	231

#	ARTICLE	IF	CITATIONS
109	Iron deficiency and cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2015, 12, 659-669.	13.8	228
110	Iron status in patients with chronic heart failure. <i>European Heart Journal</i> , 2013, 34, 827-834.	2.3	226
111	Augmented Peripheral Chemosensitivity as a Potential Input to Baroreflex Impairment and Autonomic Imbalance in Chronic Heart Failure. <i>Circulation</i> , 1997, 96, 2586-2594.	9.3	224
112	A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study. <i>Clinical Science</i> , 2007, 113, 205-212.	4.3	220
113	Identifying Pathophysiological Mechanisms in Heart Failure With Reduced Versus Preserved Ejection Fraction. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1081-1090.	5.6	216
114	Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure. <i>European Journal of Heart Failure</i> , 2010, 12, 239-248.	7.5	215
115	How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2020, 22, 391-412.	7.5	213
116	Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction. <i>Circulation</i> , 2021, 143, 298-309.	9.3	211
117	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>Kardiologia Polska</i> , 2016, 74, 1037-1147.	0.6	208
118	Iron Deficiency in Heart Failure. <i>JACC: Heart Failure</i> , 2019, 7, 36-46.	5.2	207
119	Effect of Darbepoetin Alfa on Exercise Tolerance in Anemic Patients With Symptomatic Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2007, 49, 753-762.	5.6	203
120	Physicians' adherence to guideline-recommended medications in heart failure with reduced ejection fraction: data from the QUALIFY global survey. <i>European Journal of Heart Failure</i> , 2016, 18, 514-522.	7.5	202
121	Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1444-1455.	5.6	201
122	The sympathetic/parasympathetic imbalance in heart failure with reduced ejection fraction. <i>European Heart Journal</i> , 2015, 36, 1974-1982.	2.3	198
123	Acute heart failure congestion and perfusion status: impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2019, 21, 1338-1352.	7.5	197
124	Effects of Seralaxin in Patients with Acute Heart Failure. <i>New England Journal of Medicine</i> , 2019, 381, 716-726.	30.1	195
125	The clinical significance of interleukin-6 in heart failure: results from the BIostat-CHF study. <i>European Journal of Heart Failure</i> , 2019, 21, 965-973.	7.5	195
126	Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 1512.	7.0	194

#	ARTICLE	IF	CITATIONS
127	Iron deficiency defined as depleted iron stores accompanied by unmet cellular iron requirements identifies patients at the highest risk of death after an episode of acute heart failure. <i>European Heart Journal</i> , 2014, 35, 2468-2476.	2.3	193
128	Epidemiology of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1406-1416.	0.8	192
129	Development and validation of multivariable models to predict mortality and hospitalization in patients with heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 627-634.	7.5	191
130	Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the <sc>QUALIFY</sc> international registry. <i>European Journal of Heart Failure</i> , 2017, 19, 1414-1423.	7.5	191
131	GuÃa ESC/ERS 2015 sobre diagnÃstico y tratamiento de la hipertensiÃn pulmonar. <i>Revista Espanola De Cardiologia</i> , 2016, 69, 177.e1-177.e62.	1.4	190
132	Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. <i>European Journal of Heart Failure</i> , 2013, 15, 1082-1094.	7.5	188
133	Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia. <i>European Heart Journal</i> , 2007, 28, 2208-2216.	2.3	185
134	Patient profiling in heart failure for tailoring medical therapy. A consensus document of the <sc>Heart Failure Association of the European Society of Cardiology</sc>. <i>European Journal of Heart Failure</i> , 2021, 23, 872-881.	7.5	180
135	Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches. <i>Nature Reviews Cardiology</i> , 2011, 8, 485-493.	13.8	177
136	Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure. <i>International Journal of Cardiology</i> , 2018, 258, 185-191.	1.6	177
137	Role of cardiopulmonary exercise testing in clinical stratification in heart failure. A position paper from the Committee on Exercise Physiology and Training of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2018, 20, 3-15.	7.5	169
138	Signature of circulating <sc>microRNAs</sc> in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 414-423.	7.5	168
139	The Dapagliflozin And Prevention of Adverseâ€outcomes in Heart Failure (DAPAâ€HF) trial: baseline characteristics. <i>European Journal of Heart Failure</i> , 2019, 21, 1402-1411.	7.5	168
140	Increased 90-Day Mortality in Patients With Acute Heart Failure With Elevated Copeptin. <i>Circulation: Heart Failure</i> , 2011, 4, 613-620.	4.2	167
141	Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. <i>Lancet, The</i> , 2008, 371, 228-236.	12.1	163
142	Heart Failure Association of the European Society ofÂCardiology position paper on frailty in patients with heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 1299-1305.	7.5	163
143	Evaluation of the effect of sodiumâ€glucose coâ€transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPERORâ€Reduced trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1270-1278.	7.5	162
144	Effect of ivabradine in patients with heart failure with preserved ejection fraction: the <sc>EDIFY</sc> randomized placeboâ€controlled trial. <i>European Journal of Heart Failure</i> , 2017, 19, 1495-1503.	7.5	161

#	ARTICLE	IF	CITATIONS
145	The Predictive Value of Short-Term Changes in Hemoglobin Concentration in Patients Presenting With Acute Decompensated Heart Failure. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1973-1981.	5.6	160
146	A systems <sc>BIOlogy</sc> Study to <sc>TAilored</sc> Treatment in Chronic Heart Failure: rationale, design, and baseline characteristics of <sc>BIOSTATâ€CHF</sc>. <i>European Journal of Heart Failure</i> , 2016, 18, 716-726.	7.5	157
147	Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. <i>European Heart Journal</i> , 2020, 41, 2379-2392.	2.3	156
148	Iron deficiency and health-related quality of life in chronic heart failure: Results from a multicenter European study. <i>International Journal of Cardiology</i> , 2014, 174, 268-275.	1.6	154
149	2010 Focused Update of ESC Guidelines on device therapy in heart failure. <i>European Journal of Heart Failure</i> , 2010, 12, 1143-1153.	7.5	152
150	Maintenance of serum potassium with sodium zirconium cyclosilicate (<sc>ZS</sc>â€) in heart failure patients: results from a phase 3 randomized, doubleâ€blind, placeboâ€controlled trial. <i>European Journal of Heart Failure</i> , 2015, 17, 1050-1056.	7.5	152
151	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age. <i>Circulation</i> , 2020, 141, 100-111.	9.3	152
152	Non-cardiac comorbidities in heart failure with reduced, mid-range and preserved ejection fraction. <i>International Journal of Cardiology</i> , 2018, 271, 132-139.	1.6	151
153	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator. <i>JACC: Heart Failure</i> , 2018, 6, 96-104.	5.2	150
154	Transvenous neurostimulation for central sleep apnoea: a randomised controlled trial. <i>Lancet</i> , The, 2016, 388, 974-982.	12.1	147
155	The potential role and rationale for treatment of heart failure with sodiumâ€glucose coâ€transporter 2 inhibitors. <i>European Journal of Heart Failure</i> , 2017, 19, 1390-1400.	7.5	143
156	Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure. <i>JACC: Heart Failure</i> , 2018, 6, 8-17.	5.2	143
157	Comparison of Midregional Pro-Atrial Natriuretic Peptide With N-Terminal Pro-B-Type Natriuretic Peptide in Predicting Survival in Patients With Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2007, 50, 1973-1980.	5.6	141
158	The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study. <i>European Heart Journal</i> , 2013, 34, 30-38.	2.3	141
159	Gender related differences in patients presenting with acute heart failure. Results from EuroHeart Failure Survey II. <i>European Journal of Heart Failure</i> , 2008, 10, 140-148.	7.5	139
160	Reduced Peripheral Skeletal Muscle Mass and Abnormal Reflex Physiology in Chronic Heart Failure. <i>Circulation</i> , 2006, 114, 126-134.	9.3	138
161	Treatments targeting inotropy. <i>European Heart Journal</i> , 2019, 40, 3626-3644.	2.3	138
162	Diuretic response in patients with acute decompensated heart failure: characteristics and clinical outcomeâ€an analysis from <sc>RELAXâ€AHF</sc>. <i>European Journal of Heart Failure</i> , 2014, 16, 1230-1240.	7.5	137

#	ARTICLE	IF	CITATIONS
163	European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 196-213.	7.5	137
164	Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. <i>European Heart Journal</i> , 2021, 42, 3727-3738.	2.3	137
165	Effects of Dihydrocodeine on Chemosensitivity and Exercise Tolerance in Patients With Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 1997, 29, 147-152.	5.6	136
166	Clinical Trials of Pharmacological Therapies in Acute Heart Failure Syndromes. <i>Circulation: Heart Failure</i> , 2010, 3, 314-325.	4.2	135
167	Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 499.	6.5	135
168	Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial. <i>European Journal of Heart Failure</i> , 2013, 15, 1267-1276.	7.5	134
169	Home telemonitoring in heart failure patients: the HHH study (Home or Hospital in Heart Failure). <i>European Journal of Heart Failure</i> , 2009, 11, 312-318.	7.5	132
170	Midregion Prohormone Adrenomedullin and Prognosis in Patients Presenting With Acute Dyspnea. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1057-1067.	5.6	130
171	Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. <i>European Heart Journal</i> , 2021, 42, 700-710.	2.3	130
172	A neural link to explain the "œmuscle hypothesis" of exercise intolerance in chronic heart failure. <i>American Heart Journal</i> , 1999, 137, 1050-1056.	3.1	128
173	Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2021, 42, 1203-1212.	2.3	126
174	Effects of the Adenosine A1 Receptor Antagonist Rolofylline on Renal Function in Patients With Acute Heart Failure and Renal Dysfunction. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1899-1907.	5.6	125
175	Mechanisms and Clinical Consequences of Untreated Central Sleep Apnea in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2015, 65, 72-84.	5.6	125
176	Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial. <i>European Journal of Heart Failure</i> , 2012, 14, 278-286.	7.5	124
177	Relation of heart rate and blood pressure turbulence following premature ventricular complexes to baroreflex sensitivity in chronic congestive heart failure. <i>American Journal of Cardiology</i> , 2001, 87, 737-742.	1.6	123
178	Soluble guanylate cyclase: a potential therapeutic target for heart failure. <i>Heart Failure Reviews</i> , 2013, 18, 123-134.	3.9	123
179	Rationale and design of the SOLuble guanylate Cyclase stimulator in heart failure Studies (SOCRATES). <i>European Journal of Heart Failure</i> , 2014, 16, 1026-1038.	7.5	123
180	Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018, 4, 180-188.	3.1	123

#	ARTICLE	IF	CITATIONS
181	Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. <i>Circulation</i> , 2022, 145, 184-193.	9.3	123
182	Definition and classification of Cardio-Renal Syndromes: workgroup statements from the 7th ADQI Consensus Conference. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1416-1420.	0.8	121
183	The autonomic nervous system as a therapeutic target in heart failure: a scientific position statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2017, 19, 1361-1378.	7.5	121
184	One-Year Outcomes After Transcatheter Insertion of an Interatrial Shunt Device for the Management of Heart Failure With Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2016, 9, .	4.2	119
185	Midâ€œregional proâ€œadrenomedullin as a novel predictor of mortality in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2010, 12, 484-491.	7.5	118
186	Transvenous phrenic nerve stimulation for the treatment of central sleep apnoea in heart failure. <i>European Heart Journal</i> , 2012, 33, 889-894.	2.3	118
187	The PROTECT inâ€œhospital risk model: 7â€œday outcome in patients hospitalized with acute heart failure and renal dysfunction. <i>European Journal of Heart Failure</i> , 2012, 14, 605-612.	7.5	117
188	Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry. <i>European Heart Journal</i> , 2020, 41, 3787-3797.	2.3	116
189	Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine â€œ short version. <i>European Heart Journal</i> , 2015, 36, 1958-1966.	2.3	114
190	Phrenic Nerve Stimulation for the Treatment of Central Sleep Apnea. <i>JACC: Heart Failure</i> , 2015, 3, 360-369.	5.2	114
191	Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the <scp>Translational Research Committee</scp> of the <scp>Heart Failure Association</scp> (<scp>HFA</scp>) of the <scp>European Society of Cardiology</scp> (<scp>ESC</scp>). <i>European Journal of Heart Failure</i> . 2020, 22, 2272-2289.	7.5	113
192	Symptoms, functional status and quality of life in patients with controlled and uncontrolled atrial fibrillation: data from the RealiseAF cross-sectional international registry. <i>Heart</i> , 2012, 98, 195-201.	3.8	112
193	Predicting heart failure outcome from cardiac and comorbid conditions: The 3C-HF score. <i>International Journal of Cardiology</i> , 2013, 163, 206-211.	1.6	112
194	Predictors of Postdischarge Outcomes From Information Acquired Shortly After Admission for Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 76-87.	4.2	112
195	Serial high sensitivity cardiac troponin T measurement in acute heart failure: insights from the <scp>RELAXâ€œAHF</scp> study. <i>European Journal of Heart Failure</i> , 2015, 17, 1262-1270.	7.5	112
196	Autonomic imbalance and immune activation in chronic heart failure â€œ Pathophysiological links. <i>Cardiovascular Research</i> , 2006, 70, 434-445.	3.7	111
197	Biased ligand of the angiotensin II type 1 receptor in patients with acute heart failure: a randomized, double-blind, placebo-controlled, phase IIB, dose ranging trial (BLAST-AHF). <i>European Heart Journal</i> , 2017, 38, 2364-2373.	2.3	110
198	CRT Survey II: a European Society of Cardiology survey of cardiac resynchronisation therapy in 11 088 patientsâ€œ”who is doing what to whom and how?. <i>European Journal of Heart Failure</i> , 2018, 20, 1039-1051.	7.5	110

#	ARTICLE	IF	CITATIONS
199	A randomized, double-blind, placebo-controlled, multicentre study to assess haemodynamic effects of serelaxin in patients with acute heart failure. <i>European Heart Journal</i> , 2014, 35, 431-441.	2.3	109
200	The influence of iron deficiency on the functioning of skeletal muscles: experimental evidence and clinical implications. <i>European Journal of Heart Failure</i> , 2016, 18, 762-773.	7.5	109
201	The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the Studies Investigating Co-morbidities Aggravating Heart Failure. <i>International Journal of Cardiology</i> , 2016, 205, 6-12.	1.6	109
202	Atrial Fibrillation Impairs the Diagnostic Performance of Cardiac Natriuretic Peptides in Dyspneic Patients. <i>JACC: Heart Failure</i> , 2013, 1, 192-199.	5.2	108
203	Rationale and design of Ferinject® Assessment in patients with Iron deficiency and chronic Heart Failure (FAIRâ€œCHF) study: a randomized, placeboâ€œcontrolled study of intravenous iron supplementation in patients with and without anaemia. <i>European Journal of Heart Failure</i> , 2009, 11, 1084-1091.	7.5	106
204	Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAXâ€œAHFâ€œ2 study. <i>European Journal of Heart Failure</i> , 2017, 19, 800-809.	7.5	105
205	Sodiumâ€œglucose coâ€œtransporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 1495-1503.	7.5	103
206	Effect of Estrogen Replacement Therapy on Heart Rate Variability and Heart Rate in Healthy Postmenopausal Women. <i>American Journal of Cardiology</i> , 1997, 80, 815-817.	1.6	102
207	Carotid body resection for sympathetic modulation in systolic heart failure: results from firstâ€œinâ€œman study. <i>European Journal of Heart Failure</i> , 2017, 19, 391-400.	7.5	102
208	Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Preâ€œRELAXâ€œAHF. <i>European Journal of Heart Failure</i> , 2011, 13, 961-967.	7.5	101
209	<sc>EURObservational</sc> Research Programme: a worldwide registry on peripartum cardiomyopathy (<sc>PPCM</sc>) in conjunction with the Heart Failure Association of the European Society of Cardiology Working Group on <sc>PPCM</sc>. <i>European Journal of Heart Failure</i> . 2014, 16, 583-591.	7.5	101
210	Increased blood lactate is prevalent and identifies poor prognosis in patients with acute heart failure without overt peripheral hypoperfusion. <i>European Journal of Heart Failure</i> , 2018, 20, 1011-1018.	7.5	99
211	Management of heart failure patients with <sc>COVID</sc>â€œ19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020, 22, 941-956.	7.5	99
212	Hypochloremia, Diuretic Resistance, and Outcome in Patients With Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	4.2	97
213	Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPERORâ€œPreserved trial. <i>European Journal of Heart Failure</i> , 2020, 22, 2383-2392.	7.5	97
214	Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). <i>European Heart Journal</i> , 2020, 41, 3402-3418.	2.3	97
215	Abnormal autonomic control of the cardiovascular system in syndrome X. <i>American Journal of Cardiology</i> , 1994, 73, 1174-1179.	1.6	95
216	The impact of intravenous ferric carboxymaltose on renal function: an analysis of the <sc>FAIRâ€œCHF</sc> study. <i>European Journal of Heart Failure</i> , 2015, 17, 329-339.	7.5	95

#	ARTICLE	IF	CITATIONS
217	N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes. JACC: Heart Failure, 2020, 8, 931-939.	5.2	95
218	Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial. European Heart Journal, 2023, 44, 41-50.	2.3	95
219	Circulating Estradiol and Mortality in Men With Systolic Chronic Heart Failure. JAMA - Journal of the American Medical Association, 2009, 301, 1892.	7.0	94
220	Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry. European Journal of Heart Failure, 2019, 21, 921-929.	7.5	94
221	Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan. JACC: Heart Failure, 2020, 8, 811-818.	5.2	93
222	Statin use and survival in patients with chronic heart failure – results from two observational studies with 5200 patients. International Journal of Cardiology, 2006, 112, 234-242.	1.6	91
223	Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. European Heart Journal, 2014, 35, 1041-1050.	2.3	91
224	Growth differentiation factor 15 (GDF-15) in patients admitted for acute heart failure: results from the RELAX-AHF study. European Journal of Heart Failure, 2015, 17, 1133-1143.	7.5	91
225	Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study. European Journal of Heart Failure, 2010, 12, 1130-1139.	7.5	90
226	Waist-to-hip ratio and mortality in heart failure. European Journal of Heart Failure, 2018, 20, 1269-1277.	7.5	90
227	Contemporary real life cardioversion of atrial fibrillation: Results from the multinational RHYTHM-AF study. International Journal of Cardiology, 2014, 172, 588-594.	1.6	89
228	Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial. European Heart Journal, 2009, 30, 1331-1339.	2.3	88
229	Secretory sphingomyelinase is upregulated in chronic heart failure: a second messenger system of immune activation relates to body composition, muscular functional capacity, and peripheral blood flow. European Heart Journal, 2007, 28, 821-828.	2.3	87
230	Reduction in Circulating Testosterone Relates to Exercise Capacity in Men With Chronic Heart Failure. Journal of Cardiac Failure, 2009, 15, 442-450.	1.7	87
231	The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC. European Heart Journal, 2021, 42, 1254-1269.	2.3	87
232	Contribution of skeletal muscle ergoreceptors in the human leg to respiratory control in chronic heart failure. Journal of Physiology, 2000, 529, 863-870.	2.9	86
233	Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction. JACC: Heart Failure, 2017, 5, 507-517.	5.2	86
234	Reported outcomes in the SOLuble guanylate Cyclase stimulator in heart failure patients with PRESERVED ejection fraction (SOCRATES-PRESERVED) study. European Journal of Heart Failure, 2017, 19, 782-791.	7.5	86

#	ARTICLE	IF	CITATIONS
235	Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study. <i>European Heart Journal</i> , 2011, 32, 1519-1534.	2.3	84
236	Carotid body removal for treatment of chronic systolic heart failure. <i>International Journal of Cardiology</i> , 2013, 168, 2506-2509.	1.6	84
237	A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial. <i>European Journal of Heart Failure</i> , 2017, 19, 1001-1010.	7.5	84
238	Impact of Serial Troponin Release on Outcomes in Patients With Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2011, 4, 724-732.	4.2	82
239	Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists. <i>JACC: Heart Failure</i> , 2021, 9, 254-264.	5.2	81
240	Effects of Empagliflozin on Symptoms, Physical Limitations, and Quality of Life in Patients Hospitalized for Acute Heart Failure: Results From the EMPULSE Trial. <i>Circulation</i> , 2022, 146, 279-288.	9.3	81
241	Mineralocorticoid receptor antagonist pattern of use in heart failure with reduced ejection fraction: findings from BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , 2017, 19, 1284-1293.	7.5	80
242	Sodium-glucose cotransporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2022, 24, 431-441.	7.5	80
243	Blood urea nitrogen-to-creatinine ratio in the general population and in patients with acute heart failure. <i>Heart</i> , 2017, 103, 407-413.	3.8	79
244	Iron deficiency as energetic insult to skeletal muscle in chronic diseases. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 802-815.	7.4	78
245	Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2020, 22, 999-1005.	7.5	78
246	Effect of Ejection Fraction on Clinical Outcomes in Patients Treated With Omecamtiv Mecarbil in GALACTIC-HF. <i>Journal of the American College of Cardiology</i> , 2021, 78, 97-108.	5.6	78
247	Ursodeoxycholic Acid in Patients With Chronic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2012, 59, 585-592.	5.6	77
248	The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study. <i>European Heart Journal</i> , 2021, 42, 3011-3020.	2.3	77
249	Design and Rationale of the PROTECT Study: A Placebo-controlled Randomized Study of the Selective A1 Adenosine Receptor Antagonist Rolofoylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function. <i>Journal of Cardiac Failure</i> , 2010, 16, 25-35.	1.7	76
250	Diabetes mellitus, cachexia and obesity in heart failure: rationale and design of the Studies Investigating Comorbidities Aggravating Heart Failure (SICA-HF). <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2010, 1, 187-194.	7.4	75
251	Rationale and design of ARTS: a randomized, double-blind study of BAY 948862 in patients with chronic heart failure and mild or moderate chronic kidney disease. <i>European Journal of Heart Failure</i> , 2012, 14, 668-675.	7.5	75
252	Organization of heart failure management in European Society of Cardiology member countries: survey of the Heart Failure Association of the European Society of Cardiology in collaboration with the Heart Failure National Societies/Working Groups. <i>European Journal of Heart Failure</i> , 2013, 15, 947-959.	7.5	75

#	ARTICLE	IF	CITATIONS
253	Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Studyâ€Heart Failure (ARTSâ€HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease. European Journal of Heart Failure, 2015, 17, 224-232.	7.5	75
254	Optimizing clinical use of biomarkers in highâ€risk acute heart failure patients. European Journal of Heart Failure, 2016, 18, 269-280.	7.5	75
255	Beyond the cardiorenal anaemia syndrome: recognizing the role of iron deficiency. European Journal of Heart Failure, 2012, 14, 882-886.	7.5	72
256	International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better shortâ€term outcomes in patients enrolled in Eastern Europe and Russia in the <sc>PROTECT</sc> trial. European Journal of Heart Failure, 2014, 16, 614-624.	7.5	72
257	Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies. European Heart Journal, 2015, 36, 715-723.	2.3	72
258	Association with outcomes and response to treatment of trimethylamine Nâ€oxide in heart failure: results from BIOSTATâ€CHF. European Journal of Heart Failure, 2019, 21, 877-886.	7.5	72
259	Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF. Circulation, 2022, 146, 438-449.	9.3	72
260	Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF. Circulation, 2022, 146, 980-994.	9.3	72
261	Thromboâ€embolism and antithrombotic therapy for heart failure in sinus rhythm. A Joint Consensus Document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. European Journal of Heart Failure, 2012, 14, 681-695.	7.5	71
262	Skeletal myopathy in patients with chronic heart failure: significance of anabolicâ€androgenic hormones. Journal of Cachexia, Sarcopenia and Muscle, 2014, 5, 287-296.	7.4	71
263	Abnormal liver function tests in acute heart failure: relationship with clinical characteristics and outcome in the <sc>PROTECT</sc> study. European Journal of Heart Failure, 2016, 18, 830-839.	7.5	71
264	Serial assessment of spot urine sodium predicts effectiveness of decongestion and outcome in patients with acute heart failure. European Journal of Heart Failure, 2019, 21, 624-633.	7.5	71
265	Baseline features of the VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with) Tj ETQq1 1 0.784314 rgBT /Overlock 1	7.5	70
266	Rationale and benefits of trimetazidine by acting on cardiac metabolism in heart failure. International Journal of Cardiology, 2016, 203, 909-915.	1.6	69
267	What have we learned about heart failure with midâ€range ejection fraction one year after its introduction?. European Journal of Heart Failure, 2017, 19, 1569-1573.	7.5	69
268	Sodiumâ€glucose coâ€transporter 2 inhibition in patients hospitalized for acute decompensated heart failure: rationale for and design of the <sc>EMPULSE</sc> trial. European Journal of Heart Failure, 2021, 23, 826-834.	7.5	69
269	Heart Failure Therapeutics on theâ€Basisâ€ofâ€Biased Ligand of theâ€Angiotensin-2 Typeâ€1â€Receptor. JACC: Heart Failure, 2015, 3, 193-201.	5.2	68
270	Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). European Heart Journal, 2020, 41, 2109-2117.	2.3	68

#	ARTICLE	IF	CITATIONS
271	Renal function and the effects of vericiguat in patients with worsening heart failure with reduced ejection fraction: insights from the <sc>VICTORIA</sc> (<sc>Vericiguat</sc> Global Study in) Tj ETQq1 1 0.7843 14 rgB48 Overlock	10.2	68
272	Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction. <i>Annals of Internal Medicine</i> , 2022, 175, 820-830.	10.2	68
273	Trimetazidine in cardiovascular medicine. <i>International Journal of Cardiology</i> , 2019, 293, 39-44.	1.6	67
274	<sc>Heart Failure Association</sc> of the <sc>European Society of Cardiology</sc> update on sodiumâumlacron; glucose coâumlacron; transporter 2 inhibitors in heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 1984-1986.	7.5	66
275	Hyperuricaemia predicts poor outcome in patients with mild to moderate chronic heart failure. <i>International Journal of Cardiology</i> , 2007, 115, 151-155.	1.6	65
276	Shortâumlacron; term Mortality Risk in Emergency Department Acute Heart Failure. <i>Academic Emergency Medicine</i> , 2011, 18, 947-958.	1.9	65
277	Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm. <i>Thrombosis and Haemostasis</i> , 2012, 108, 1009-1022.	3.5	65
278	Phrenic nerve stimulation to treat patients with central sleep apnoea and heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 1746-1754.	7.5	65
279	The 12-week progressive quadriceps resistance training improves muscle strength, exercise capacity and quality of life in patients with stable chronic heart failure. <i>International Journal of Cardiology</i> , 2008, 130, 36-43.	1.6	64
280	The additive burden of iron deficiency in the cardiorenalâumlacron; anaemia axis: scope of a problem and its consequences. <i>European Journal of Heart Failure</i> , 2014, 16, 655-662.	7.5	64
281	Effect of dapagliflozin on anaemia in <sc>DAPAâumlacron; HF</sc>. <i>European Journal of Heart Failure</i> , 2021, 23, 617-628.	7.5	64
282	Inâumlacron; hospital worsening heart failure. <i>European Journal of Heart Failure</i> , 2015, 17, 1104-1113.	7.5	63
283	Detection and significance of a discrete very low frequency rhythm in RR interval variability in chronic congestive heart failure. <i>American Journal of Cardiology</i> , 1996, 77, 1320-1326.	1.6	62
284	Ventilatory response to exercise correlates with impaired heart rate variability in patients with chronic congestive heart failure. <i>American Journal of Cardiology</i> , 1998, 82, 338-344.	1.6	60
285	Design of the RELAXin in Acute Heart Failure Study. <i>American Heart Journal</i> , 2012, 163, 149-155.e1.	3.1	60
286	Renal Function Trajectories and Clinical Outcomes in Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2014, 7, 59-67.	4.2	60
287	Prognostic Significance of Creatinine Increases During an Acute Heart Failure Admission in Patients With and Without Residual Congestion. <i>Circulation: Heart Failure</i> , 2018, 11, e004644.	4.2	60
288	Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60âumlacron; day outcomes in the PROTECT pilot study. <i>European Journal of Heart Failure</i> , 2010, 12, 499-507.	7.5	59

#	ARTICLE	IF	CITATIONS
289	Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1337-1348.	5.6	59
290	Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF. <i>European Heart Journal</i> , 2013, 34, 3128-3136.	2.3	58
291	Impaired hepato-renal function defined by the MELD XI score as prognosticator in acute heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 1518-1521.	7.5	57
292	Potassium and the use of renin-angiotensin-aldosterone system inhibitors in heart failure with reduced ejection fraction: data from BIOSTAT-CHF. <i>European Journal of Heart Failure</i> , 2018, 20, 923-930.	7.5	57
293	Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction. <i>Circulation</i> , 2020, 142, 1623-1632.	9.3	57
294	Effect of Serelaxin on Mode of Death in Acute Heart Failure. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1591-1598.	5.6	56
295	Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on Acute Admissions at the Emergency and Cardiology Departments Across Europe. <i>American Journal of Medicine</i> , 2021, 134, 482-489.	1.4	56
296	Overview and meta-analysis of randomised trials of amiodarone in chronic heart failure. <i>International Journal of Cardiology</i> , 1998, 66, 1-10.	1.6	55
297	Use of biomarkers to establish potential role and function of circulating microRNAs in acute heart failure. <i>International Journal of Cardiology</i> , 2016, 224, 231-239.	1.6	55
298	Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure. <i>International Journal of Cardiology</i> , 2018, 253, 84-90.	1.6	55
299	Iron deficiency and red cell indices in patients with heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 114-122.	7.5	55
300	Concentric vs. eccentric remodelling in heart failure with reduced ejection fraction: clinical characteristics, pathophysiology and response to treatment. <i>European Journal of Heart Failure</i> , 2020, 22, 1147-1155.	7.5	55
301	Bone mineral status and bone loss over time in men with chronic systolic heart failure and their clinical and hormonal determinants. <i>European Journal of Heart Failure</i> , 2009, 11, 28-38.	7.5	54
302	Urinary levels of novel kidney biomarkers and risk of true worsening renal function and mortality in patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 760-767.	7.5	54
303	High soluble transferrin receptor in patients with heart failure: a measure of iron deficiency and a strong predictor of mortality. <i>European Journal of Heart Failure</i> , 2021, 23, 919-932.	7.5	54
304	Sex-specific acute heart failure phenotypes and outcomes from PROTECT. <i>European Journal of Heart Failure</i> , 2013, 15, 1374-1381.	7.5	53
305	A network analysis to compare biomarker profiles in patients with and without diabetes mellitus in acute heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 1310-1320.	7.5	53
306	Dissociation between blood pressure and heart rate response to hypoxia after bilateral carotid body removal in men with systolic heart failure. <i>Experimental Physiology</i> , 2014, 99, 552-561.	2.0	52

#	ARTICLE	IF	CITATIONS
307	Transcatheter Interatrial Shunt Device for the Treatment of Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	4.2	52
308	Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. <i>Diabetes Care</i> , 2021, 44, 586-594.	9.1	52
309	Silver paper: The future of health promotion and preventive actions, basic research, and clinical aspects of age-related disease. <i>Aging Clinical and Experimental Research</i> , 2009, 21, 376-385.	2.9	51
310	Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure. <i>Heart Failure Reviews</i> , 2013, 18, 107-122.	3.9	51
311	Patient journey after admission for acute heart failure: length of stay, 30-day readmission and 90-day mortality. <i>European Journal of Heart Failure</i> , 2016, 18, 1041-1050.	7.5	51
312	Health economic assessment of ferric carboxymaltose in patients with iron deficiency and chronic heart failure based on the FAIR-HF trial: an analysis for the UK. <i>European Journal of Heart Failure</i> , 2012, 14, 782-790.	7.5	50
313	Use of High-Sensitivity Troponin T to Identify Patients With Acute Heart Failure at Lower Risk for Adverse Outcomes. <i>JACC: Heart Failure</i> , 2016, 4, 591-599.	5.2	50
314	Resting and exercise haemodynamics in relation to six-minute walk test in patients with heart failure and preserved ejection fraction. <i>European Journal of Heart Failure</i> , 2018, 20, 715-722.	7.5	49
315	Comparing biomarker profiles of patients with heart failure: atrial fibrillation vs. sinus rhythm and reduced vs. preserved ejection fraction. <i>European Heart Journal</i> , 2018, 39, 3867-3875.	2.3	49
316	Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: <sc>GALACTIC-HF</sc> baseline characteristics and comparison with contemporary clinical trials. <i>European Journal of Heart Failure</i> , 2020, 22, 2160-2171.	7.5	49
317	Biomarkers in kidney and heart disease. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 62-74.	0.8	48
318	Influence of age, race, sex, and body mass index on interpretation of midregional pro atrial natriuretic peptide for the diagnosis of acute heart failure: results from the BACH multinational study. <i>European Journal of Heart Failure</i> , 2012, 14, 22-31.	7.5	48
319	Acute heart failure in elderly patients: worse outcomes and differential utility of standard prognostic variables. Insights from the <sc>PROTECT</sc> trial. <i>European Journal of Heart Failure</i> , 2015, 17, 109-118.	7.5	48
320	Left Ventricular Ejection Fraction and Risk of Stroke and Cardiac Events in Heart Failure. <i>Stroke</i> , 2016, 47, 2031-2037.	5.3	48
321	Corrigendum to "ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008" [Eur Heart J 2008;29:2388-2442 and Eur J Heart Fail 2008;10:933-989]. <i>European Heart Journal</i> , 2008, 29, 3069-3069.	2.3	47
322	Design of the remedÅ System Pivotal Trial: A Prospective, Randomized Study in the Use of Respiratory Rhythm Management to Treat Central Sleep Apnea. <i>Journal of Cardiac Failure</i> , 2015, 21, 892-902.	1.7	46
323	Worsening Heart Failure Following Admission for Acute Heart Failure. <i>JACC: Heart Failure</i> , 2015, 3, 395-403.	5.2	46
324	Impact of an interatrial shunt device on survival and heart failure hospitalization in patients with preserved ejection fraction. <i>ESC Heart Failure</i> , 2019, 6, 62-69.	3.1	46

#	ARTICLE	IF	CITATIONS
325	Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. <i>European Journal of Heart Failure</i> , 2021, 23, 527-540.	7.5	45
326	Clinical Predictors and Hemodynamic Consequences of Elevated Peripheral Chemosensitivity in Optimally Treated Men With Chronic Systolic Heart Failure. <i>Journal of Cardiac Failure</i> , 2013, 19, 408-415.	1.7	44
327	Transvenous stimulation of the phrenic nerve for the treatment of central sleep apnoea: 12 months' experience with the remeÄ“^{Â®} System. <i>European Journal of Heart Failure</i> , 2016, 18, 1386-1393.	7.5	44
328	Clinical correlates and prognostic impact of impaired iron storage versus impaired iron transport in an international cohort of 1821 patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2017, 243, 360-366.	1.6	44
329	The PCSK9-LDL Receptor Axis and Outcomes in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 70, 2128-2136.	5.6	44
330	Rationale and design of the AFFIRMÂ€AHF trial: a randomised, double-blind, placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalisations and mortality in iron-deficient patients admitted for acute heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 1651-1658.	7.5	44
331	Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis. <i>European Heart Journal</i> , 2023, 44, 5077-5091.	2.3	44
332	Serum Potassium Levels and Outcome in Acute Heart Failure (Data from the PROTECT and COACH) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.6	43
333	Molecular Changes in Myocardium in the Course of Anemia or Iron Deficiency. <i>Heart Failure Clinics</i> , 2010, 6, 295-304.	2.4	42
334	Distance covered during a six-minute walk test predicts long-term cardiovascular mortality and hospitalisation rates in men with systolic heart failure: an observational study. <i>Journal of Physiotherapy</i> , 2013, 59, 177-187.	3.2	42
335	Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 24-34.	11.3	42
336	The Safety of an Adenosine A1-Receptor Antagonist, Rolofylline, in Patients with Acute Heart Failure and Renal Impairment. <i>Drug Safety</i> , 2012, 35, 233-244.	3.2	41
337	Depleted iron stores are associated with inspiratory muscle weakness independently of skeletal muscle mass in men with systolic chronic heart failure. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2018, 9, 547-556.	7.4	41
338	Rationale and design of the EMPERIALÂ€Preserved and EMPERIALÂ€Reduced trials of empagliflozin in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2019, 21, 932-942.	7.5	41
339	Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. <i>European Journal of Heart Failure</i> , 2021, 23, 1662-1672.	7.5	41
340	Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from <sc>DAPAÂ€HF</sc>. <i>European Journal of Heart Failure</i> , 2022, 24, 513-525.	7.5	41
341	Gonadal and adrenal androgen deficiencies as independent predictors of increased cardiovascular mortality in men with type II diabetes mellitus and stable coronary artery disease. <i>International Journal of Cardiology</i> , 2010, 143, 343-348.	1.6	40
342	Comparison of invasive and non-invasive measurements of haemodynamic parameters in patients with advanced heart failure. <i>Journal of Cardiovascular Medicine</i> , 2011, 12, 773-778.	1.5	40

#	ARTICLE	IF	CITATIONS
343	Liver Function, In-Hospital, and Post-Discharge Clinical Outcome in Patients With Acute Heart Failure—Results From the Relaxin for the Treatment of Patients With Acute Heart Failure Study. <i>Journal of Cardiac Failure</i> , 2014, 20, 407-413.	1.7	40
344	Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study. <i>European Journal of Heart Failure</i> , 2019, 21, 1459-1467.	7.5	40
345	Long-term efficacy and safety of phrenic nerve stimulation for the treatment of central sleep apnea. <i>Sleep</i> , 2019, 42, .	1.1	40
346	Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1300-1312.	7.5	40
347	Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure. <i>Annals of Internal Medicine</i> , 2021, 174, 1065-1072.	10.2	40
348	Impaired baroreflex sensitivity and sympathovagal balance in syndrome X. <i>American Journal of Cardiology</i> , 1998, 82, 862-868.	1.6	39
349	Effect of altering conditions of the sequence method on baroreflex sensitivity. <i>Journal of Hypertension</i> , 2001, 19, 1279-1287.	0.5	39
350	Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF. <i>European Journal of Heart Failure</i> , 2013, 15, 456-464.	7.5	39
351	Patogenia y presentaci3n cl3nica de la insuficiencia cardiaca aguda. <i>Revista Espanola De Cardiologia</i> , 2015, 68, 331-337.	1.4	39
352	Bone marrow iron depletion is common in patients with coronary artery disease. <i>International Journal of Cardiology</i> , 2015, 182, 517-522.	1.6	39
353	2016 ESC and ACC/AHA/HFSA heart failure guideline update – what is new and why is it important?. <i>Nature Reviews Cardiology</i> , 2016, 13, 623-628.	13.8	39
354	Effectiveness of screening for atrial fibrillation and its determinants. A meta-analysis. <i>PLoS ONE</i> , 2019, 14, e0213198.	2.5	39
355	Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. <i>Circulation</i> , 2021, 143, 1962-1972.	9.3	39
356	The new oral adenosine A1 receptor agonist capadenoson in male patients with stable angina. <i>Clinical Research in Cardiology</i> , 2012, 101, 585-591.	3.5	38
357	Benefit of Warfarin Compared With Aspirin in Patients With Heart Failure in Sinus Rhythm. <i>Circulation: Heart Failure</i> , 2013, 6, 988-997.	4.2	38
358	Rationale and design of the CONFIRM-HF study: a double-blind, randomized, placebo-controlled study to assess the effects of intravenous ferric carboxymaltose on functional capacity in patients with chronic heart failure and iron deficiency. <i>ESC Heart Failure</i> , 2014, 1, 52-58.	3.1	38
359	Could the two-minute step test be an alternative to the six-minute walk test for patients with systolic heart failure?. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1307-1313.	1.8	38
360	Renal profiling based on estimated glomerular filtration rate and spot urine sodium identifies high-risk acute heart failure patients. <i>European Journal of Heart Failure</i> , 2021, 23, 729-739.	7.5	38

#	ARTICLE	IF	CITATIONS
361	<sc>COVID</sc>â€19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021, 23, 1806-1818.	7.5	38
362	Structural and functional abnormalities in iron-depleted heart. <i>Heart Failure Reviews</i> , 2019, 24, 269-277.	3.9	37
363	Clinical value of preâ€discharge bioâ€adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission. <i>European Journal of Heart Failure</i> , 2020, 22, 683-691.	7.5	37
364	Standardizing care for acute decompensated heart failure in a large megatrial: The approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF). <i>American Heart Journal</i> , 2009, 157, 219-228.	3.1	36
365	Normal electrocardiographic and echocardiographic (M-mode and two-dimensional) values in Polish Landrace pigs. <i>Acta Veterinaria Scandinavica</i> , 2014, 56, 54.	1.6	36
366	Clinical Profile and Prognostic Value of Anemia at the Time of Admission and Discharge Among Patients Hospitalized for Heart Failure With Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 401-408.	4.2	36
367	MicroRNAs relate to early worsening of renal function in patients with acute heart failure. <i>International Journal of Cardiology</i> , 2016, 203, 564-569.	1.6	36
368	Iron Therapy in Patients with Heart Failure and Iron Deficiency: Review of Iron Preparations for Practitioners. <i>American Journal of Cardiovascular Drugs</i> , 2017, 17, 183-201.	2.3	36
369	Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure. <i>Journal of the American College of Cardiology</i> , 2018, 71, 386-398.	5.6	36
370	Rationale and Design of the VITALITY-HFpEF Trial. <i>Circulation: Heart Failure</i> , 2019, 12, e005998.	4.2	36
371	Plasma kidney injury moleculeâ€1 in heart failure: renal mechanisms and clinical outcome. <i>European Journal of Heart Failure</i> , 2016, 18, 641-649.	7.5	35
372	Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2016, 9, .	4.2	35
373	Procalcitonin-based indication of bacterial infection identifies high risk acute heart failure patients. <i>International Journal of Cardiology</i> , 2016, 204, 164-171.	1.6	35
374	Plasma biomarkers to predict or rule out early postâ€discharge events after hospitalization for acute heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 728-738.	7.5	35
375	GuÃa ESC/EACTS 2017 sobre el tratamiento de las valvulopatÃas. <i>Revista Espanola De Cardiologia</i> , 2018, 71, 110.e1-110.e47.	1.4	35
376	Central and Peripheral Determinants of Exercise Capacity in Heart Failure Patients With Preserved Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 321-332.	5.2	35
377	Multiâ€organ dysfunction/injury on admission identifies acute heart failure patients at high risk of poor outcome. <i>European Journal of Heart Failure</i> , 2019, 21, 744-750.	7.5	35
378	Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the <sc>DAPAâ€HF</sc> trial. <i>European Journal of Heart Failure</i> , 2021, 23, 601-613.	7.5	35

#	ARTICLE	IF	CITATIONS
379	Impact of mitral regurgitation in patients with worsening heart failure: insights from <sc>BIOSTATâ€CHF</sc>. European Journal of Heart Failure, 2021, 23, 1750-1758.	7.5	35
380	Identification of Chronic Heart Failure Patients with a High 12-Month Mortality Risk Using Biomarkers Including Plasma C-Terminal Pro-Endothelin-1. PLoS ONE, 2011, 6, e14506.	2.5	35
381	Consequences of peripheral chemoreflex inhibition with lowâ€dose dopamine in humans. Journal of Physiology, 2014, 592, 1295-1308.	2.9	34
382	Impact of atrial fibrillation on rest and exercise haemodynamics in heart failure with midâ€range and preserved ejection fraction. European Journal of Heart Failure, 2017, 19, 1690-1697.	7.5	34
383	Clinical Correlates and Prognostic Value of Proenkephalin in Acute and Chronic Heart Failure. Journal of Cardiac Failure, 2017, 23, 231-239.	1.7	34
384	Comparison between spectral analysis and the phenylephrine method for the assessment of baroreflex sensitivity in chronic heart failure. Clinical Science, 1999, 97, 503-513.	4.3	33
385	Cardiac autonomic dysfunction in AIDS is not secondary to heart failure. International Journal of Cardiology, 2000, 74, 133-137.	1.6	33
386	Anemia in chronic heart failure: Can we treat? What to treat?. Heart Failure Reviews, 2012, 17, 203-210.	3.9	33
387	Relationship between baseline systolic blood pressure and long-term outcomes in acute heart failure patients treated with TRV027: an exploratory subgroup analysis of BLAST-AHF. Clinical Research in Cardiology, 2018, 107, 170-181.	3.5	33
388	The year in cardiology 2018: heart failure. European Heart Journal, 2019, 40, 651-661.	2.3	33
389	Prediction of AF in Heartâ€Failure With Preserved Ejection Fraction. JACC: Cardiovascular Imaging, 2021, 14, 131-144.	6.0	33
390	Transvenous Phrenic Nerve Stimulation for Treatment of Central Sleep Apnea: Five-Year Safety and Efficacy Outcomes. Nature and Science of Sleep, 2021, Volume 13, 515-526.	2.8	33
391	Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in <sc>DAPAâ€HF</sc>. European Journal of Heart Failure, 2022, 24, 1066-1076.	7.5	33
392	The association of lower testosterone level with coronary artery disease in postmenopausal women. International Journal of Cardiology, 2003, 87, 53-57.	1.6	32
393	Deficiencies in circulating testosterone and dehydroepiandrosterone sulphate, and depression in men with systolic chronic heart failure. European Journal of Heart Failure, 2010, 12, 966-973.	7.5	32
394	Prevention of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. Nephrology Dialysis Transplantation, 2010, 25, 1777-1784.	0.8	32
395	Exercise programs for LVAD supported patients: A snapshot from the ESC affiliated countries. International Journal of Cardiology, 2015, 201, 215-219.	1.6	32
396	A combined clinical and biomarker approach to predict diuretic response in acute heart failure. Clinical Research in Cardiology, 2016, 105, 145-153.	3.5	32

#	ARTICLE	IF	CITATIONS
397	Rationale for and design of the <sc>TRUE&AHF</sc> trial: the effects of ularitide on the short&term clinical course and long&term mortality of patients with acute heart failure. <i>European Journal of Heart Failure</i> , 2017, 19, 673-681.	7.5	32
398	Proteomic diversity of high&density lipoprotein explains its association with clinical outcome in patients with heart failure. <i>European Journal of Heart Failure</i> , 2018, 20, 260-267.	7.5	32
399	Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction. <i>Circulation</i> , 2022, 146, 1046-1055.	9.3	32
400	Reproducibility of Heart Rate Variability Measures in Patients with Chronic Heart Failure. <i>Clinical Science</i> , 1996, 91, 391-398.	4.3	31
401	Comparison of treatment initiation with bisoprolol vs. enalapril in chronic heart failure patients: rationale and design of CIBIS-III. <i>European Journal of Heart Failure</i> , 2004, 6, 493-500.	7.5	31
402	Gu&a de pr&ctica cl&nica de la ESC sobre diagn&stico y tratamiento de la insuficiencia cardiaca aguda y cr&nica 2012. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 938.e1-938.e59.	1.4	31
403	Sustained 12 Month Benefit of Phrenic Nerve Stimulation for Central Sleep Apnea. <i>American Journal of Cardiology</i> , 2018, 121, 1400-1408.	1.6	31
404	Rationale and design of a multicentre, randomized, placebo&controlled trial of mirabegron, a Beta3&adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3&left ventricular hypertrophy (Beta3&LVH). <i>ESC Heart Failure</i> , 2018, 5, 830-841.	3.1	31
405	Plasma proteomic approach in patients with&heart failure: insights into pathogenesis of&disease progression and potential novel treatment targets. <i>European Journal of Heart Failure</i> , 2020, 22, 70-80.	7.5	31
406	Determinants of quality of life of patients with heart failure and iron deficiency treated with ferric carboxymaltose: FAIR-HF sub-analysis. <i>International Journal of Cardiology</i> , 2013, 168, 3878-3883.	1.6	30
407	Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction&. <i>European Journal of Heart Failure</i> , 2013, 15, 679-689.	7.5	30
408	Cognitive Decline Over Time in Patients With Systolic Heart&Failure. <i>JACC: Heart Failure</i> , 2019, 7, 1042-1053.	5.2	30
409	Efficacy and safety of sodium&glucose co&transporter <sc>2</sc> inhibition according to left ventricular ejection fraction in <sc>DAPA&HF</sc>. <i>European Journal of Heart Failure</i> , 2020, 22, 1247-1258.	7.5	30
410	Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 678.	6.5	30
411	Empagliflozin Improves Outcomes in&Patients With Heart&Failure and Preserved Ejection Fraction Irrespective of Age. <i>Journal of the American College of Cardiology</i> , 2022, 80, 1-18.	5.6	30
412	Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER. <i>Circulation</i> , 2023, 147, 624-634.	9.3	30
413	Effects of selective carotid body stimulation with adenosine in conscious humans. <i>Journal of Physiology</i> , 2016, 594, 6225-6240.	2.9	29
414	Controlled decongestion by Reprieve therapy in acute heart failure: results of the TARGET&1 and TARGET&2 studies. <i>European Journal of Heart Failure</i> , 2019, 21, 1079-1087.	7.5	29

#	ARTICLE	IF	CITATIONS
415	Heart failure in COVID-19: the multicentre, multinational PCHF-COVICAV registry. ESC Heart Failure, 2021, 8, 4955-4967.	3.1	29
416	Effects of an outpatient intervention comprising nurse-led non-invasive assessments, telemedicine support and remote cardiologists' decisions in patients with heart failure (<scp>AMULET</scp> study): a randomised controlled trial. European Journal of Heart Failure, 2022, 24, 565-577.	7.5	29
417	Transient autonomic dysfunction precedes ST-segment depression in patients with syndrome X. American Journal of Cardiology, 1996, 77, 942-947.	1.6	28
418	Effects of amiodarone on the P-wave triggered signal-averaged electrocardiogram in patients with paroxysmal atrial fibrillation and coronary artery disease. American Journal of Cardiology, 1999, 83, 112-114.	1.6	28
419	Hyperhomocysteinemia in patients with symptomatic chronic heart failure: Prevalence and prognostic importance—pilot study. Atherosclerosis, 2007, 194, 408-414.	0.8	28
420	The effect of intravenous ferric carboxymaltose on red cell distribution width: a subanalysis of the FAIR-HF study. European Journal of Heart Failure, 2013, 15, 756-762.	7.5	28
421	Hyperkalemia and Treatment With RAAS Inhibitors During Acute Heart Failure Hospitalizations and Their Association With Mortality. JACC: Heart Failure, 2019, 7, 970-979.	5.2	28
422	The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure. European Journal of Heart Failure, 2009, 11, 1071-1077.	7.5	27
423	Changes in autonomic balance in patients with decompensated chronic heart failure. Clinical Autonomic Research, 2011, 21, 47-54.	2.5	27
424	<scp>CHA ₂ DS ₂ -VASc</scp> score and adverse outcomes in patients with heart failure with reduced ejection fraction and sinus rhythm. European Journal of Heart Failure, 2016, 18, 1261-1266.	7.5	27
425	Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline-directed medical therapy in heart failure with reduced ejection fraction. European Journal of Heart Failure, 2021, 23, 1999-2007.	7.5	27
426	Heart rhythms, ventricular arrhythmias, and death in chronic heart failure. Journal of Cardiac Failure, 1996, 2, 177-183.	1.7	26
427	Vitamin B ₁₂ and folate deficiency in chronic heart failure. Heart, 2015, 101, 302-310.	3.8	26
428	Left atrial volume and cardiovascular outcomes in systolic heart failure: effect of antithrombotic treatment. ESC Heart Failure, 2018, 5, 800-808.	3.1	26
429	Guidance on the management of left ventricular assist device (<scp>LVAD</scp>) supported patients for the non-<scp>LVAD</scp> specialist healthcare provider: executive summary. European Journal of Heart Failure, 2021, 23, 1597-1609.	7.5	26
430	Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA). Circulation, 2021, 144, 1489-1499.	9.3	26
431	Liver function tests in patients with acute heart failure. Polish Archives of Internal Medicine, 2012, 122, 471-479.	0.4	26
432	Home telemonitoring of vital signs and cardiorespiratory signals in heart failure patients: System architecture and feasibility of the HHH model. International Journal of Cardiology, 2007, 120, 371-379.	1.6	25

#	ARTICLE	IF	CITATIONS
433	Early vs. late worsening heart failure during acute heart failure hospitalization: insights from the PROTECT trial. <i>European Journal of Heart Failure</i> , 2015, 17, 697-706.	7.5	25
434	Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis. <i>European Journal of Heart Failure</i> , 2020, 22, 315-329.	7.5	25
435	Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of <sc>DAPAâ€HF</sc>. <i>European Journal of Heart Failure</i> , 2021, 23, 632-643.	7.5	25
436	Expression and Complex Formation of MMP9, MMP2, NGAL, and TIMP1 in Porcine Myocardium but Not in Skeletal Muscles in Male Pigs with Tachycardia-Induced Systolic Heart Failure. <i>BioMed Research International</i> , 2013, 2013, 1-12.	2.0	24
437	Relationship between left ventricular ejection fraction and cardiovascular outcomes following hospitalization for heart failure: insights from the RELAXâ€AHFâ€2 trial. <i>European Journal of Heart Failure</i> , 2020, 22, 726-738.	7.5	24
438	Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost-effectiveness analysis utilising <sc>AFFIRMâ€AHF</sc>. <i>European Journal of Heart Failure</i> , 2021, 23, 1687-1697.	7.5	24
439	Additional burden of iron deficiency in heart failure patients beyond the cardio-renal anaemia syndrome: findings from the <sc>BIOSTATâ€CHF</sc> study. <i>European Journal of Heart Failure</i> , 2022, 24, 192-204.	7.5	24
440	Heart Failure in Patients With Atrial Fibrillation Is Associated With a High Symptom and Hospitalization Burden: The <sc>RealiseAF</sc> Survey. <i>Clinical Cardiology</i> , 2013, 36, 766-774.	1.9	23
441	Hepatorenal dysfunction identifies high-risk patients with acute heart failure: insights from the RELAXâ€AHF trial. <i>ESC Heart Failure</i> , 2019, 6, 1188-1198.	3.1	23
442	Clinical, respiratory, haemodynamic, and metabolic determinants of lactate in heart failure. <i>Kardiologia Polska</i> , 2019, 77, 47-52.	0.6	23
443	Very-low-frequency oscillations in heart rate and blood pressure in periodic breathing: role of the cardiovascular limb of the hypoxic chemoreflex. <i>Clinical Science</i> , 2000, 99, 125-132.	4.3	22
444	The Effects of Adenosine A1 Receptor Antagonism in Patients With Acute Decompensated Heart Failure and Worsening Renal Function: The REACH UP Study. <i>Journal of Cardiac Failure</i> , 2010, 16, 714-719.	1.7	22
445	Effects of ivabradine in patients with stable angina receiving beta-blockers according to baseline heart rate: an analysis of the ASSOCIATE study. <i>International Journal of Cardiology</i> , 2013, 168, 789-794.	1.6	22
446	Circulating testosterone and estradiol, autonomic balance and baroreflex sensitivity in middle-aged and elderly men with heart failure. <i>Aging Male</i> , 2013, 16, 58-66.	2.0	22
447	European Cardiac Resynchronization Therapy Survey II: rationale and design. <i>Europace</i> , 2015, 17, 137-141.	1.6	22
448	Higher doses of loop diuretics limit uptitration of angiotensin-converting enzyme inhibitors in patients with heart failure and reduced ejection fraction. <i>Clinical Research in Cardiology</i> , 2020, 109, 1048-1059.	3.5	22
449	Both iron excess and iron depletion impair viability of rat H9C2 cardiomyocytes and L6G8C5 myocytes. <i>Kardiologia Polska</i> , 2017, 75, 267-275.	0.6	22
450	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial. <i>Circulation: Heart Failure</i> , 2021, 14, CIRCHEARTFAILURE121008837.	4.2	22

#	ARTICLE	IF	CITATIONS
451	Echocardiographic determinants of mortality in patients >67 years of age with chronic heart failure. American Journal of Cardiology, 2000, 86, 158-161.	1.6	21
452	Japanese-Western Consensus Meeting on Biomarkers. International Heart Journal, 2011, 52, 253-265.	1.0	21
453	Quality of Anticoagulation Control in Preventing Adverse Events in Patients With Heart Failure in Sinus Rhythm. Circulation: Heart Failure, 2015, 8, 504-509.	4.2	21
454	Non-adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from <sc>SHIFT</sc>. European Journal of Heart Failure, 2016, 18, 672-683.	7.5	21
455	Guía ESC 2016 sobre prevención de la enfermedad cardiovascular en la práctica clínica. Revista Espanola De Cardiología, 2016, 69, 939.e1-939.e87.	1.4	21
456	Cardiovascular stress biomarker assessment of middle-aged non-athlete marathon runners. European Journal of Preventive Cardiology, 2019, 26, 318-327.	1.8	21
457	Patient factors associated with titration of medical therapy in patients with heart failure with reduced ejection fraction: data from the QUALIFY international registry. ESC Heart Failure, 2021, 8, 861-871.	3.1	21
458	Spot urine sodium in acute heart failure: differences in prognostic value on admission and discharge. ESC Heart Failure, 2021, 8, 2597-2602.	3.1	21
459	Activation of the NF- κ B system in peripheral blood leukocytes from patients with chronic heart failure. European Journal of Heart Failure, 2005, 7, 984-990.	7.5	20
460	RHYTHM-AF: design of an international registry on cardioversion of atrial fibrillation and characteristics of participating centers. BMC Cardiovascular Disorders, 2012, 12, 85.	1.7	20
461	Health locus of control and the sense of self-efficacy in patients with systolic heart failure: a pilot study. Patient Preference and Adherence, 2013, 7, 337.	1.9	20
462	Temporal trends in secondary prevention in myocardial infarction patients discharged with left ventricular systolic dysfunction in Poland. European Journal of Preventive Cardiology, 2018, 25, 960-969.	1.8	20
463	Effect of ferric carboxymaltose on calculated plasma volume status and clinical congestion: a FAIR-HF substudy. ESC Heart Failure, 2019, 6, 621-628.	3.1	20
464	Effects of a Novel Nitroxyl Donor in Acute Heart Failure. JACC: Heart Failure, 2021, 9, 146-157.	5.2	20
465	Is acute heart failure a distinctive disorder? An analysis from <sc>BIOSTAT-HF</sc>. European Journal of Heart Failure, 2021, 23, 43-57.	7.5	20
466	Impact of periodic breathing on measurement of oxygen uptake and respiratory exchange ratio during cardiopulmonary exercise testing. Clinical Science, 2002, 103, 543-552.	4.3	19
467	Development of porcine model of chronic tachycardia-induced cardiomyopathy. International Journal of Cardiology, 2011, 153, 36-41.	1.6	19
468	Evaluación económica de la utilización de hierro carboximaltosa en pacientes con deficiencia de hierro e insuficiencia cardiaca crónica en España. Revista Espanola De Cardiología, 2015, 68, 846-851.	1.4	19

#	ARTICLE	IF	CITATIONS
469	Elevated lactate in acute heart failure patients with intracellular iron deficiency as identifier of poor outcome. <i>Kardiologia Polska</i> , 2019, 77, 347-354.	0.6	19
470	Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2022, 24, 782-790.	7.5	19
471	Atrial disease and heart failure: the common soil hypothesis proposed by the Heart Failure Association of the European Society of Cardiology. <i>European Heart Journal</i> , 2022, 43, 863-867.	2.3	19
472	Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial. <i>European Journal of Heart Failure</i> , 2022, 24, 1614-1622.	7.5	19
473	Comparison between spectral analysis and the phenylephrine method for the assessment of baroreflex sensitivity in chronic heart failure. <i>Clinical Science</i> , 1999, 97, 503.	4.3	18
474	Pathophysiological and clinical relevance of simplified monitoring of nocturnal breathing disorders in heart failure patients. <i>European Journal of Heart Failure</i> , 2009, 11, 264-272.	7.5	18
475	Value of serum pregnancy-associated plasma protein A for predicting cardiovascular events among patients presenting with cardiac chest pain. <i>Cmaj</i> , 2013, 185, E295-E303.	4.1	18
476	Influence of the availability of iron during hypoxia on the genes associated with apoptotic activity and local iron metabolism in rat H9C2 cardiomyocytes and L6G8C5 skeletal myocytes. <i>Molecular Medicine Reports</i> , 2016, 14, 3969-3977.	2.5	18
477	Compensatory post-diuretic renal sodium reabsorption is not a dominant mechanism of diuretic resistance in acute heart failure. <i>European Heart Journal</i> , 2021, 42, 4468-4477.	2.3	18
478	Biomarkers of Myocardial Injury and Remodeling in Heart Failure. <i>Journal of Personalized Medicine</i> , 2022, 12, 799.	2.6	18
479	New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment. <i>European Journal of Heart Failure</i> , 2017, 19, 718-727.	7.5	17
480	Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure: insights from the RELAX-AHF study. <i>Clinical Research in Cardiology</i> , 2017, 106, 280-292.	3.5	17
481	Plasma Neutrophil Gelatinase-Associated Lipocalin and Predicting Clinically Relevant Worsening Renal Function in Acute Heart Failure. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1470.	4.2	17
482	Acute heart failure: lessons learned, roads ahead. <i>European Journal of Heart Failure</i> , 2018, 20, 842-850.	7.5	17
483	Trajectories of Changes in Renal Function in Patients with Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2019, 25, 866-874.	1.7	17
484	Oxygenation pattern and compensatory responses to hypoxia and hypercapnia following bilateral carotid body resection in humans. <i>Journal of Physiology</i> , 2021, 599, 2323-2340.	2.9	17
485	Distinct renin/aldosterone activity profiles correlate with renal function, natriuretic response, decongestive ability and prognosis in acute heart failure. <i>International Journal of Cardiology</i> , 2021, 345, 54-60.	1.6	17
486	Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency. <i>European Journal of Heart Failure</i> , 2022, 24, 821-832.	7.5	17

#	ARTICLE	IF	CITATIONS
487	Reproducibility of Heart Rate Variability Indices during Exercise Stress Testing and Inotrope Infusion in Chronic Heart Failure Patients. <i>Clinical Science</i> , 1996, 91, 87-88.	0.0	16
488	Excessive ventilation during early phase of exercise: A new predictor of poor long-term outcome in patients with chronic heart failure. <i>European Journal of Heart Failure</i> , 2007, 9, 1024-1031.	7.5	16
489	Effect on Mode of Death of Heart Failure Treatment Started with Bisoprolol Followed by Enalapril, Compared to the Opposite Order: Results of the Randomized CIBIS III Trial. <i>Cardiovascular Therapeutics</i> , 2011, 29, 89-98.	2.5	16
490	Anemia in Heart Failure: an Overview of Current Concepts. <i>Future Cardiology</i> , 2011, 7, 119-129.	1.1	16
491	Pathogenesis and Clinical Presentation of Acute Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 331-337.	0.7	16
492	Effects of serelaxin in acute heart failure patients with renal impairment: results from RELAX-AHF. <i>Clinical Research in Cardiology</i> , 2016, 105, 727-737.	3.5	16
493	Iron Depletion Affects Genes Encoding Mitochondrial Electron Transport Chain and Genes of Non-Oxidative Metabolism, Pyruvate Kinase and Lactate Dehydrogenase, in Primary Human Cardiac Myocytes Cultured upon Mechanical Stretch. <i>Cells</i> , 2018, 7, 175.	4.3	16
494	Genetic risk and atrial fibrillation in patients with heart failure. <i>European Journal of Heart Failure</i> , 2020, 22, 519-527.	7.5	16
495	Rationale and design of the AMULET study: A new Model of telemedical care in patients with heart failure. <i>ESC Heart Failure</i> , 2021, 8, 2569-2579.	3.1	16
496	Haemodynamic effects of rolofylline in the treatment of patients with heart failure and impaired renal function. <i>European Journal of Heart Failure</i> , 2010, 12, 1238-1246.	7.5	15
497	Cognitive Function in Ambulatory Patients with Systolic Heart Failure: Insights from the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial. <i>PLoS ONE</i> , 2014, 9, e113447.	2.5	15
498	Higher serum phosphorus is associated with catabolic/anabolic imbalance in heart failure. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2015, 6, 325-334.	7.4	15
499	A Cost-effectiveness Analysis of Ferric Carboxymaltose in Patients With Iron Deficiency and Chronic Heart Failure in Spain. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 846-851.	0.7	15
500	Elevated plasma endothelin-1 is related to low natriuresis, clinical signs of congestion, and poor outcome in acute heart failure. <i>ESC Heart Failure</i> , 2020, 7, 3536-3544.	3.1	15
501	The influence of metformin and the presence of type 2 diabetes mellitus on mortality and hospitalisation in patients with heart failure. <i>Kardiologia Polska</i> , 2018, 76, 1336-1343.	0.6	15
502	Nuclear factor- κ B activity in peripheral blood mononuclear cells in cachectic and non-cachectic patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2007, 122, 111-116.	1.6	14
503	Actualizaci3n detallada de las gu3as de la ESC para el manejo de la fibrilaci3n auricular de 2012. <i>Revista Espanola De Cardiologia</i> , 2013, 66, 54.e1-54.e24.	1.4	14
504	Gu3a de Pr3ctica Cl3nica de la ESC 2013 sobre diagn3stico y tratamiento de la cardiopat3a isqu3mica estable. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 135.e1-135.e81.	1.4	14

#	ARTICLE	IF	CITATIONS
505	Could gonadal and adrenal androgen deficiencies contribute to the depressive symptoms in men with systolic heart failure?. <i>Aging Male</i> , 2016, 19, 221-230.	2.0	14
506	The first prognostic model for stroke and death in patients with systolic heart failure. <i>Journal of Cardiology</i> , 2016, 68, 100-103.	1.9	14
507	Guía ESC 2016 sobre el diagnóstico y tratamiento de la fibrilación auricular, desarrollada en colaboración con la EACTS. <i>Revista Espanola De Cardiologia</i> , 2017, 70, 50.e1-50.e84.	1.4	14
508	Corrigendum to "2017 ESC/EACTS Guidelines for the management of valvular heart disease" [Eur J Cardiothorac Surg 2017;52:616-664]. <i>European Journal of Cardio-thoracic Surgery</i> , 2017, 52, 832-832.	1.4	14
509	Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e007879.	4.2	14
510	On the search for the right definition of heart failure with preserved ejection fraction. <i>Cardiology Journal</i> , 2020, 27, 449-468.	1.3	14
511	Vericiguat and Health-Related Quality of Life in Patients With Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial. <i>Circulation: Heart Failure</i> , 2022, 15, .	4.2	14
512	Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis. <i>Circulation</i> , 2023, 147, 1640-1653.	9.3	14
513	Lack of decrease in plasma N-terminal pro-brain natriuretic peptide identifies acute heart failure patients with very poor outcome. <i>International Journal of Cardiology</i> , 2008, 129, 373-378.	1.6	13
514	European silver paper on the future of health promotion and preventive actions, basic research, and clinical aspects of age-related disease. <i>European Journal of Ageing</i> , 2009, 6, 51-57.	2.7	13
515	Relation of Longitudinal Changes in Quality of Life Assessments to Changes in Functional Capacity in Patients With Heart Failure With and Without Anemia. <i>American Journal of Cardiology</i> , 2016, 117, 1482-1487.	1.6	13
516	Patterns of dyspnoea onset in patients with acute heart failure: clinical and prognostic implications. <i>ESC Heart Failure</i> , 2019, 6, 16-26.	3.1	13
517	Sleep disordered breathing in patients with heart failure. <i>Cardiology Journal</i> , 2013, 20, 345-355.	1.3	13
518	Could an analysis of mean corpuscular volume help to improve risk stratification in non-anemic patients with acute myocardial infarction?. <i>Cardiology Journal</i> , 2015, 22, 421-427.	1.3	13
519	Coordinated heart failure care in Poland: towards optimal organisation of the health care system. <i>Kardiologia Polska</i> , 2018, 76, 479-487.	0.6	13
520	Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2022, 10, 52-64.	5.2	13
521	Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF. <i>Circulation</i> , 2023, 147, 1670-1683.	9.3	13
522	ESC Guidelines for the Diagnosis And Treatment of Acute And Chronic Heart Failure 2008. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2008, 61, 1329.	0.7	12

#	ARTICLE	IF	CITATIONS
523	Permutation criteria to evaluate multiple clinical endpoints in a proof-of-concept study: lessons from Pre-RELAX-AHF. <i>Clinical Research in Cardiology</i> , 2011, 100, 745-753.	3.5	12
524	Mid-regional pro-adrenomedullin improves disposition strategies for patients with acute dyspnoea: results from the BACH trial. <i>Emergency Medicine Journal</i> , 2013, 30, 633-637.	2.0	12
525	Increased body fat is associated with potentiation of blood pressure response to hypoxia in healthy men: relations with insulin and leptin. <i>Clinical Autonomic Research</i> , 2016, 26, 107-116.	2.5	12
526	Acute heart failure in the young: Clinical characteristics and biomarker profiles. <i>International Journal of Cardiology</i> , 2016, 221, 1067-1072.	1.6	12
527	Relationship between central sleep apnea and Cheyne-Stokes Respiration. <i>International Journal of Cardiology</i> , 2016, 206, S8-S12.	1.6	12
528	Associations of Body Mass Index With Laboratory and Biomarkers in Patients With Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2017, 10, .	4.2	12
529	Iron limitation promotes the atrophy of skeletal myocytes, whereas iron supplementation prevents this process in the hypoxic conditions. <i>International Journal of Molecular Medicine</i> , 2018, 41, 2678-2686.	4.1	12
530	Assessment of baroreflex sensitivity has no prognostic value in contemporary, optimally managed patients with mild-to-moderate heart failure with reduced ejection fraction: a retrospective analysis of 5-year survival. <i>European Journal of Heart Failure</i> , 2019, 21, 50-58.	7.5	12
531	Cause of Death in Patients With Acute Heart Failure. <i>JACC: Heart Failure</i> , 2020, 8, 999-1008.	5.2	12
532	Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 1298.	6.5	12
533	Iron deficiency contributes to resistance to endogenous erythropoietin in anaemic heart failure patients. <i>European Journal of Heart Failure</i> , 2021, 23, 1677-1686.	7.5	12
534	Amended <sc>STRONG–HF</sc> study design. <i>European Journal of Heart Failure</i> , 2021, 23, 1981-1982.	7.5	12
535	HFA of the ESC position paper on the management of LVAD-supported patients for the non-LVAD specialist healthcare provider Part 3: at the hospital and discharge. <i>ESC Heart Failure</i> , 2021, 8, 4425-4443.	3.1	12
536	Population of Polish patients participating in the Heart Failure Pilot Survey (ESC-HF Pilot). <i>Kardiologia Polska</i> , 2013, 71, 234-240.	0.6	12
537	Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure. <i>European Journal of Heart Failure</i> , 2022, 24, 308-320.	7.5	12
538	Clinical impact of changes in mitral regurgitation severity after medical therapy optimization in heart failure. <i>Clinical Research in Cardiology</i> , 2022, 111, 912-923.	3.5	12
539	Clinical implications of low estimated protein intake in patients with heart failure. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 1762-1770.	7.4	12
540	Minimally Clinically Important Difference in Health Status Scores in Patients With HFrEF vs HFpEF. <i>JACC: Heart Failure</i> , 2022, 10, 651-661.	5.2	12

#	ARTICLE	IF	CITATIONS
541	The win ratio method in heart failure trials: lessons learnt from <scp>EMPULSE</scp>. <i>European Journal of Heart Failure</i> , 2023, 25, 632-641.	7.5	12
542	Clinical and Echocardiographic Factors Associated With New-Onset Atrial Fibrillation in Heart Failure – Subanalysis of the WARCEF Trial. <i>Circulation Journal</i> , 2016, 80, 619-626.	1.6	11
543	Effects of serelaxin on the outcome of patients with or without substantial peripheral edema: A subgroup analysis from the RELAX-AHF trial. <i>American Heart Journal</i> , 2017, 190, 113-122.	3.1	11
544	Evaluation of Skeletal Muscle Function and Effects of Early Rehabilitation during Acute Heart Failure: Rationale and Study Design. <i>BioMed Research International</i> , 2018, 2018, 1-8.	2.0	11
545	Hypoxic tachycardia is not a result of increased respiratory activity in healthy subjects. <i>Experimental Physiology</i> , 2019, 104, 476-489.	2.0	11
546	Heart rate and blood pressure monitoring in heart failure. <i>European Heart Journal Supplements</i> , 2019, 21, M13-M16.	0.1	11
547	Monitoring of iron status in patients with heart failure. <i>European Heart Journal Supplements</i> , 2019, 21, M32-M35.	0.1	11
548	Mega-trials in heart failure: effects of dilution in examination of new therapies. <i>European Journal of Heart Failure</i> , 2020, 22, 1698-1707.	7.5	11
549	Developments in Exercise Capacity Assessment in Heart Failure Clinical Trials and the Rationale for the Design of METEORIC-HF. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121008970.	4.2	11
550	P-wave signal-averaged electrocardiogram in patients with idiopathic mitral valve prolapse syndrome and supraventricular arrhythmias. <i>International Journal of Cardiology</i> , 1995, 50, 175-180.	1.6	10
551	Is plasma renin activity associated with worse outcomes in acute heart failure? A secondary analysis from the BLAST-AHF trial. <i>European Journal of Heart Failure</i> , 2019, 21, 1561-1570.	7.5	10
552	Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2019, 108, 797-805.	3.5	10
553	Expression of sex steroid receptors and aromatase in adipose tissue in different body regions in men with coronary artery disease with and without ischemic systolic heart failure. <i>Aging Male</i> , 2020, 23, 141-153.	2.0	10
554	Distinct clinical phenotypes of congestion in acute heart failure: characteristics, treatment response, and outcomes. <i>ESC Heart Failure</i> , 2020, 7, 3830-3840.	3.1	10
555	Association of left ventricular ejection fraction with worsening renal function in patients with acute heart failure: insights from the <scp>RELAX-AHF</scp> study. <i>European Journal of Heart Failure</i> , 2021, 23, 58-67.	7.5	10
556	Comparison of left ventricular longitudinal systolic function parameters in the prediction of adverse outcome in heart failure with preserved ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 1531-1540.	3.1	10
557	Pathophysiology of Advanced Heart Failure. <i>Heart Failure Clinics</i> , 2021, 17, 519-531.	2.4	10
558	Hospitalisation length and prognosis in heart failure patients. <i>Kardiologia Polska</i> , 2017, 75, 323-331.	0.6	10

#	ARTICLE	IF	CITATIONS
559	Persistent hyperlactataemia is related to high rates of in-hospital adverse events and poor outcome in acute heart failure. <i>Kardiologia Polska</i> , 2019, 77, 355-362.	0.6	10
560	Costs of management of patients with coronary artery disease in Poland: the multicenter RECENT study. <i>Polish Archives of Internal Medicine</i> , 2012, 122, 599-607.	0.4	10
561	Atrial fibrillation in outpatients with stable coronary artery disease : results from the multicenter RECENT study. <i>Polish Archives of Internal Medicine</i> , 2015, 125, 162-171.	0.4	10
562	Relationship of Dapagliflozin With Serum Sodium. <i>JACC: Heart Failure</i> , 2022, 10, 306-318.	5.2	10
563	Very-low-frequency oscillations in heart rate and blood pressure in periodic breathing: role of the cardiovascular limb of the hypoxic chemoreflex. <i>Clinical Science</i> , 2000, 99, 125.	4.3	9
564	The influence of confounders in the analysis of mid-regional pro-atrial natriuretic peptide in patients with chronic heart failure. <i>International Journal of Cardiology</i> , 2016, 219, 84-91.	1.6	9
565	Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial. <i>Clinical Research in Cardiology</i> , 2017, 106, 444-456.	3.5	9
566	Day vs night: Does time of presentation matter in acute heart failure? A secondary analysis from the RELAX-AHF trial. <i>American Heart Journal</i> , 2017, 187, 62-69.	3.1	9
567	Identifying Subpopulations with Distinct Response to Treatment Using Plasma Biomarkers in Acute Heart Failure: Results from the PROTECT Trial. <i>Cardiovascular Drugs and Therapy</i> , 2017, 31, 281-293.	2.8	9
568	Heart Failure Association of the European Society of Cardiology position paper on the management of left ventricular assist device-supported patients for the non-left ventricular assist device specialist healthcare provider: Part 2: at the emergency department. <i>ESC Heart Failure</i> , 2021, 8, 4409-4424.	3.1	9
569	Enzyme replacement therapy in Fabry disease in Poland – position statement. <i>Polish Archives of Internal Medicine</i> , 2019, 130, 91-97.	0.4	9
570	Adherence to systolic heart failure guidelines in ambulatory care in Poland – data from the international QUALIFY survey. <i>Polish Archives of Internal Medicine</i> , 2017, 127, 657-665.	0.4	9
571	Responder analysis for improvement in 6-min walk test with ferric carboxymaltose in patients with heart failure with reduced ejection fraction and iron deficiency. <i>European Journal of Heart Failure</i> , 2022, 24, 833-842.	7.5	9
572	Impact of periodic breathing on and : a quantitative approach by Fourier analysis. <i>Respiration Physiology</i> , 1999, 118, 247-255.	2.9	8
573	EPO's rescue mission in acute myocardial infarction: still more hopes than evidence. <i>European Heart Journal</i> , 2010, 31, 2577-2579.	2.3	8
574	Anabolic deficiencies in men with systolic heart failure: do co-morbidities and therapies really contribute significantly?. <i>Aging Male</i> , 2013, 16, 123-131.	2.0	8
575	Comparison of clinical profile and management of outpatients with heart failure with reduced left ventricular ejection fraction treated by general practitioners and cardiologists in contemporary Poland: The results from the DATA-HELP registry. <i>International Journal of Cardiology</i> , 2014, 176, 852-858.	1.6	8
576	Clinical research Patients with heart failure and concomitant chronic obstructive pulmonary disease participating in the Heart Failure Pilot Survey (ESC-HF Pilot) – Polish population. <i>Archives of Medical Science</i> , 2015, 4, 743-750.	0.9	8

#	ARTICLE	IF	CITATIONS
577	Iron deficiency in heart failure: Impact on response to cardiac resynchronization therapy. <i>International Journal of Cardiology</i> , 2016, 222, 133-134.	1.6	8
578	The Effects of a Marathon Effort on Psychomotor Performance and Catecholamine Concentration in Runners over 50 Years of Age. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 2067.	2.6	8
579	Nurse-led ambulatory care supported by non-invasive haemodynamic assessment after acute heart failure decompensation. <i>ESC Heart Failure</i> , 2021, 8, 1018-1026.	3.1	8
580	Primary Human Cardiomyocytes and Cardiofibroblasts Treated with Sera from Myocarditis Patients Exhibit an Increased Iron Demand and Complex Changes in the Gene Expression. <i>Cells</i> , 2021, 10, 818.	4.3	8
581	The Additive Prognostic Value of Serial Plasma Interleukin-6 Levels over Changes in Brain Natriuretic Peptide in Patients with Acute Heart Failure. <i>Journal of Cardiac Failure</i> , 2021, 27, 808-811.	1.7	8
582	Clinical Outcome Predictions for the Vericiguat Global Study in Subjects With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial. <i>Journal of Cardiac Failure</i> , 2021, 27, 949-956.	1.7	8
583	Heart failure: preventing disease and death worldwide. <i>ESC Heart Failure</i> , 2014, 1, n/a-n/a.	3.1	8
584	Validation of transurethral intra-abdominal pressure measurement in acute heart failure. <i>Polish Archives of Internal Medicine</i> , 2018, 128, 403-405.	0.4	8
585	Comprehensive Heart Failure Care pilot study: starting point and expected developments. <i>Kardiologia Polska</i> , 2019, 77, 994-999.	0.6	8
586	Testosterone deficiency in men with heart failure: pathophysiology and its clinical, prognostic and therapeutic implications. <i>Kardiologia Polska</i> , 2014, 72, 403-409.	0.6	8
587	Association of Early Blood Pressure Decrease and Renal Function With Prognosis in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 890-903.	5.2	8
588	Acute hyperoxia reveals tonic influence of peripheral chemoreceptors on systemic vascular resistance in heart failure patients. <i>Scientific Reports</i> , 2021, 11, 20823.	3.4	8
589	Novel Phenotyping for Acute Heart Failure—Unsupervised Machine Learning-Based Approach. <i>Biomedicines</i> , 2022, 10, 1514.	3.3	8
590	Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial. <i>Circulation</i> , 2024, 149, 1627-1638.	9.3	8
591	Role of Catecholamines and Sympathetic Activation as a Risk Factor for Coronary Artery Disease. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 1995, 2, 222-228.	2.8	7
592	European Silver Paper. Documento europeo sobre el futuro de la promoción de la salud y las acciones preventivas, la investigación básica y los aspectos clínicos de las enfermedades relacionadas con el envejecimiento. <i>Revista Española De Geriatria Y Gerontología</i> , 2009, 44, 61-65.	0.4	7
593	Guía de práctica clínica para la valoración del riesgo cardiaco preoperatorio y el manejo cardiaco perioperatorio en la cirugía no cardiaca. <i>Revista Española De Cardiología</i> , 2009, 62, 1467.e1-1467.e56.	1.4	7
594	Bleeding Risk and Antithrombotic Strategy in Patients With Sinus Rhythm and Heart Failure With Reduced Ejection Fraction Treated With Warfarin or Aspirin. <i>American Journal of Cardiology</i> , 2015, 116, 904-912.	1.6	7

#	ARTICLE	IF	CITATIONS
595	Iron Deficiency Treatment in Patients with Heart Failure. Handbook of Experimental Pharmacology, 2017, 243, 561-576.	0.0	7
596	Using matrix assisted laser desorption ionisation mass spectrometry (MALDI-MS) profiling in order to predict clinical outcomes of patients with heart failure. Clinical Proteomics, 2018, 15, 35.	2.2	7
597	Effects of running a marathon on irisin concentration in men aged over 50. Journal of Physiological Sciences, 2019, 69, 79-84.	2.2	7
598	Association between mortality and implantable cardioverter-defibrillators by aetiology of heart failure: a propensity-matched analysis of the WARCEF trial. ESC Heart Failure, 2019, 6, 297-307.	3.1	7
599	10-year trends in hospitalization rates due to heart failure and related in-hospital mortality in Poland (2010-2019). ESC Heart Failure, 2020, 7, 3365-3373.	3.1	7
600	Geographical differences in heart failure characteristics and treatment across Europe: results from the BIOSTAT-CHF study. Clinical Research in Cardiology, 2020, 109, 967-977.	3.5	7
601	Targeting Iron Deficiency in Heart Failure: Existing Evidence and Future Expectations. Circulation: Heart Failure, 2021, 14, e008299.	4.2	7
602	HFA of the ESC Position paper on the management of LVAD supported patients for the non LVAD specialist healthcare provider Part 1: Introduction and at the non-hospital settings in the community. ESC Heart Failure, 2021, 8, 4394-4408.	3.1	7
603	Cardiac emergencies during the coronavirus disease 2019 pandemic in the light of the current evidence. Kardiologia Polska, 2020, 78, 818-824.	0.6	7
604	Human carotid bodies as a therapeutic target: new insights from a clinician's perspective. Kardiologia Polska, 2018, 76, 1426-1433.	0.6	7
605	True worsening renal function identifies patients with acute heart failure with an ominous outcome. Polish Archives of Internal Medicine, 2019, 129, 357-360.	0.4	7
606	Repetitive use of LEvosimendan in Ambulatory Heart Failure patients (LEIA-HF) - The rationale and study design. Advances in Medical Sciences, 2022, 67, 18-22.	2.2	7
607	Differences in the Biomarker Profile of De Novo Acute Heart Failure versus Decompensation of Chronic Heart Failure. Biomolecules, 2021, 11, 1701.	4.2	7
608	Performance Comparison of Au-Based and Au-Free AlGaIn/GaN HEMT on Silicon. IEEE Transactions on Electron Devices, 2022, 69, 1014-1019.	3.2	7
609	Assessment of Proximal Tubular Function by Tubular Maximum Phosphate Reabsorption Capacity in Heart Failure. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 228-239.	4.4	7
610	Treatment of Anemia With Darbepoetin Alfa in Heart Failure. Congestive Heart Failure, 2010, 16, 87-95.	1.9	6
611	Serum phosphorus level is related to degree of clinical response to up-titration of heart failure pharmacotherapy. International Journal of Cardiology, 2014, 177, 248-254.	1.6	6
612	Risk-based evaluation of efficacy of rolofylline in patients hospitalized with acute heart failure - Post-hoc analysis of the PROTECT trial. International Journal of Cardiology, 2016, 223, 967-975.	1.6	6

#	ARTICLE	IF	CITATIONS
613	Drug therapy in elderly heart failure patients. <i>European Heart Journal Supplements</i> , 2019, 21, L8-L11.	0.1	6
614	Intravenous iron supplementation: novel anti-remodelling therapy for patients with heart failure?. <i>European Heart Journal</i> , 2021, , .	2.3	6
615	Impact of digoxin on risk of death in heart failure patients treated with b-blockers. Results from Polish part of ESC Heart Failure Long-Term Registry. <i>Kardiologia Polska</i> , 2018, 76, 1064-1072.	0.6	6
616	Hemosiderin Accumulation in Liver Decreases Iron Availability in Tachycardia-Induced Porcine Congestive Heart Failure Model. <i>International Journal of Molecular Sciences</i> , 2022, 23, 1026.	4.2	6
617	The Role of Pharmacological Treatment in the Chemoreflex Modulation. <i>Frontiers in Physiology</i> , 0, 13, .	2.8	6
618	Background Medical Therapy and Clinical Outcomes From the VICTORIA Trial. <i>Circulation: Heart Failure</i> , 2023, 16, .	4.2	6
619	Sex Hormone-Binding Globulin and Heart Failure: a Passive Carrier of Steroid Hormones or an Active Hormone Itself?. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2009, 62, 1353-1355.	0.7	5
620	The effect of diabetes on the diagnostic and prognostic performance of mid-region pro-atrial natriuretic peptide and mid-region pro-adrenomedullin in patients with acute dyspnea. <i>Biomarkers</i> , 2012, 17, 490-497.	1.8	5
621	Late-onset hypogonadism in men with systolic heart failure: prevalence, clinical associates, and impact on long-term survival. <i>ESC Heart Failure</i> , 2014, 1, 41-51.	3.1	5
622	Psychological Gender of Men With Systolic Heart Failure. <i>American Journal of Men's Health</i> , 2014, 8, 249-257.	1.6	5
623	Sex differences in porcine left ventricular myocardial remodeling due to right ventricular pacing. <i>Biology of Sex Differences</i> , 2015, 6, 32.	4.2	5
624	Iohexol clearance is superior to creatinine-based renal function estimating equations in detecting short-term renal function decline in chronic heart failure. <i>Croatian Medical Journal</i> , 2015, 56, 531-541.	0.9	5
625	Psychological aspects of heart failure – beyond depression, anxiety and quality of life. <i>Health Psychology Report</i> , 2015, 3, 99-114.	1.0	5
626	CUPID 2: A Phase 2b Trial Investigating the Efficacy and Safety of the Intracoronary Administration of AAV1/SERCA2a in Patients with Advanced Heart Failure. <i>Journal of Cardiac Failure</i> , 2015, 21, 939-940.	1.7	5
627	Looking at the heart failure through the prism of liver dysfunction. <i>European Journal of Heart Failure</i> , 2020, 22, 1672-1674.	7.5	5
628	Not all fluid overloads are the same: some practical considerations for better decongestion. <i>European Journal of Heart Failure</i> , 2021, 23, 1106-1109.	7.5	5
629	Iron status, catabolic/anabolic balance, and skeletal muscle performance in men with heart failure with reduced ejection fraction. <i>Cardiology Journal</i> , 2021, 28, 391-401.	1.3	5
630	Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials. <i>Circulation</i> , 2021, 144, 1265-1267.	9.3	5

#	ARTICLE	IF	CITATIONS
631	Nordic Walking May Safely Increase the Intensity of Exercise Training in Healthy Subjects and in Patients with Chronic Heart Failure. <i>Advances in Clinical and Experimental Medicine</i> , 2016, 25, 145-149.	1.6	5
632	Andropausal syndrome in men with systolic heart failure. <i>Polish Archives of Internal Medicine</i> , 2013, 123, 156-169.	0.4	5
633	Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF. <i>JACC: Heart Failure</i> , 2022, 10, 104-118.	5.2	5
634	Impact of mitral regurgitation in patients with acute heart failure: insights from the RELAX-AHF trial. <i>European Journal of Heart Failure</i> , 2023, 25, 541-552.	7.5	5
635	Acute Heart Failure Is a Malignant Process: But We Can Induce Remission. <i>Journal of the American Heart Association</i> , 2023, 12, .	3.9	5
636	Globulina transportadora de hormonas sexuales: ¿un transportador pasivo de hormonas esteroideas o una molécula hormonal activa en la insuficiencia cardiaca?. <i>Revista Espanola De Cardiologia</i> , 2009, 62, 1353-1355.	1.4	4
637	'Iron deficiency: an ominous sign in patients with systolic chronic heart failure' [<i>Eur Heart J</i> 2010;31:1872-1880, doi:10.1093/eurheartj/ehq158]. <i>European Heart Journal</i> , 2011, 32, 1054-1054.	2.3	4
638	Association of quality of life with anticoagulant control in patients with heart failure: The Warfarin and Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial. <i>International Journal of Cardiology</i> , 2014, 177, 715-717.	1.6	4
639	Current and emerging pharmacologic options for the management of patients with chronic and acute decompensated heart failure. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 517-534.	3.2	4
640	Proportional pulse pressure relates to cardiac index in stabilized acute heart failure patients. <i>Clinical and Experimental Hypertension</i> , 2018, 40, 637-643.	1.3	4
641	Expert opinion of the Heart Failure Working Group of the Polish Cardiac Society on the use of dapagliflozin in the treatment of heart failure with reduced ejection fraction. <i>Kardiologia Polska</i> , 2021, 79, 363-370.	0.6	4
642	Intravenous ferric carboxymaltose does not provide benefits in reperfused acute myocardial infarction in the rat with normal iron status. <i>Biomedicine and Pharmacotherapy</i> , 2021, 141, 111893.	5.8	4
643	Role of skeletal muscle perfusion and insulin resistance in the effect of dietary sodium on heart function in overweight. <i>ESC Heart Failure</i> , 2021, 8, 5304-5315.	3.1	4
644	Abnormal serum calcium levels are associated with clinical response to maximization of heart failure therapy. <i>Polish Archives of Internal Medicine</i> , 2015, 125, 54-64.	0.4	4
645	Iron deficiency in heart failure: a 2020 update. <i>Kardiologia Polska</i> , 2019, 77, 1134-1139.	0.6	4
646	Cardioversion differences among first detected episode, paroxysmal, and persistent atrial fibrillation patients in the RHYTHM AF registry in Poland. <i>Cardiology Journal</i> , 2015, 22, 453-458.	1.3	4
647	Acute heart failure in patients admitted to the emergency department with acute myocardial infarction. <i>Kardiologia Polska</i> , 2017, 75, 306-315.	0.6	4
648	Impact of Rapid Up-Titration of Guideline-Directed Medical Therapies on Quality of Life: Insights From the STRONG-HF Trial. <i>Circulation: Heart Failure</i> , 2024, 17, .	4.2	4

#	ARTICLE	IF	CITATIONS
649	Highlights of the 2006 Scientific Sessions of the European Society of Cardiology. Journal of the American College of Cardiology, 2006, 48, 2564-2574.	5.6	3
650	Changes in Dyspnea during Treatment of Acute Heart Failure Are Correlated with Clinical Signs, Rehospitalizations and Mortality. Results from the Pre-RELAX-AHF Trial. Journal of Cardiac Failure, 2009, 15, S62-S63.	1.7	3
651	Hypoglycaemia in diabetic patients: highly undesirable by cardiologists. European Heart Journal, 2013, 34, 3102-3105.	2.3	3
652	Anaemia (and iron deficiency?) in aortic stenosis – a bystander or a potential therapeutic target?. European Journal of Heart Failure, 2015, 17, 994-996.	7.5	3
653	Aspirin Does Not Increase Heart Failure Events in Heart Failure Patients. JACC: Heart Failure, 2017, 5, 603-610.	5.2	3
654	Central Chemoreceptor Sensitivity Is Not Enhanced in Contemporary Patients With Chronic Systolic Heart Failure Receiving Optimal Treatment. Journal of Cardiac Failure, 2017, 23, 83-87.	1.7	3
655	The story of carotid body resection for HF. European Heart Journal, 2017, 38, 3481-3482.	2.3	3
656	Heart Failure Severity and Quality of Warfarin Anticoagulation Control (From the WARCEF Trial). American Journal of Cardiology, 2018, 122, 821-827.	1.6	3
657	Myocardial iron content in non-ischaemic cardiomyopathy: how much is known?. European Journal of Heart Failure, 2020, 22, 2047-2048.	7.5	3
658	Catabolic/Anabolic Imbalance Is Accompanied by Changes of Left Ventricular Steroid Nuclear Receptor Expression in Tachycardia-Induced Systolic Heart Failure in Male Pigs. Journal of Cardiac Failure, 2021, 27, 682-692.	1.7	3
659	Sexual dimorphism in socioeconomic differences regarding the risk factors, symptomatology and management of patients with stable coronary artery disease in Poland. Cardiology Journal, 2015, 22, 487-494.	1.3	3
660	Demographic and clinical characteristics of patients with atrial fibrillation and cardioversion as planned therapeutic options in the International Registry on Cardioversion of Atrial Fibrillation RHYTHM-AF Polish substudy. Kardiologia Polska, 2014, 72, 700-706.	0.6	3
661	Phrenic nerve stimulation in patients with central sleep apnea: a single-center experience from pilot and pivotal trials evaluating the remedÅ System. Kardiologia Polska, 2019, 77, 553-560.	0.6	3
662	Recommendations on the use of innovative medical technologies in cardiology and cardiac surgery and solutions leading to increased availability for Polish patients. Cardiology Journal, 2019, 26, 114-129.	1.3	3
663	Cardioversion of Atrial Fibrillation (RHYTHM-AF) International Registry in Poland. Cardiology Journal, 2014, 21, 484-491.	1.3	3
664	Medical emergency team interventions in patients with ST-segment elevation myocardial infarction in Poland in 2018. Kardiologia Polska, 2020, 78, 292-299.	0.6	3
665	Effects of Dapagliflozin in Asian Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. JACC Asia, 2022, 2, 139-153.	2.2	3
666	Treatment of advanced chronic heart failure with normal left ventricular ejection fraction. Response to the letter by Dr. Martinez-Selles. European Journal of Heart Failure, 2007, 9, 1224-1225.	7.5	2

#	ARTICLE	IF	CITATIONS
667	Vasodilators in Acute Heart Failure (AHF): Does Blood Pressure Matter? Results from Pre-Relax-AHF. <i>Journal of Cardiac Failure</i> , 2009, 15, S74.	1.7	2
668	Changes in parasympathetic system in medulla oblongata in male pigs in the course of tachycardia-induced cardiomyopathy. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2013, 177, 253-259.	2.7	2
669	Site enrollment rate, outcomes, and study drug effects in a multicenter trial. Results from RELAX-AHF. <i>International Journal of Cardiology</i> , 2018, 253, 91-96.	1.6	2
670	Seat belts-related behaviors in car drivers with cardiac implantable electronic devices. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2019, 42, 400-406.	1.2	2
671	Frailty and cognitive impairment are predictive of takotsubo syndrome following pacemaker implantation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2020, 43, 730-736.	1.2	2
672	Antiplatelets in acute coronary syndrome in Poland – from guidelines to clinical practice. <i>Postępy W Kardiologii Interwencyjnej</i> , 2021, 17, 141-154.	0.2	2
673	InterAtrial Shunt Device (IASD®) implantation – a novel treatment method for heart failure with preserved ejection fraction. <i>Kardiologia Polska</i> , 2017, 75, 736-741.	0.6	2
674	Relationship between the CHA2DS2-VASc score and atrial fibrillation in patients hospitalised due to heart failure. <i>Kardiologia Polska</i> , 2019, 77, 380-385.	0.6	2
675	Clinical profile and management of outpatients with non-ischemic and non-hypertensive systolic heart failure: Analysis of the Polish DATA-HELP registry. <i>Cardiology Journal</i> , 2018, 25, 512-520.	1.3	2
676	Prognostic importance of serum troponin concentration in patients with an implanted cardioverter-defibrillator admitted to the emergency department due to electric shock. <i>Kardiologia Polska</i> , 2019, 77, 618-623.	0.6	2
677	Chloroquine and hydroxychloroquine for the prevention and therapy of coronavirus disease 2019: new hopes and old cardiovascular concerns. <i>Kardiologia Polska</i> , 2020, 78, 811-817.	0.6	2
678	Early Hemodynamic Changes following Surgical Ablation of the Right Greater Splanchnic Nerve for the Treatment of Heart Failure with Preserved Ejection Fraction. <i>Journal of Clinical Medicine</i> , 2022, 11, 1063.	2.5	2
679	Iron deficiency as an emerging therapeutic target in patients stabilized after an episode of acute heart failure. <i>Cardiology Journal</i> , 2021, 28, 962-969.	1.3	2
680	Contribution of Peripheral Chemoreceptors to Exercise Intolerance in Heart Failure. <i>Frontiers in Physiology</i> , 2022, 13, 878363.	2.8	2
681	Novel Biomarkers of Renal Dysfunction and Congestion in Heart Failure. <i>Journal of Personalized Medicine</i> , 2022, 12, 898.	2.6	2
682	Inflammatory activation biomarker profile after marathon running and its impact on cardiovascular stress in amateur middle-aged male runners. <i>Advances in Clinical and Experimental Medicine</i> , 2023, 32, 0-0.	1.6	2
683	Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause. <i>Journal of the American Heart Association</i> , 2023, 12, .	3.9	2
684	Redefining Iron Deficiency in Patients With Chronic Heart Failure. <i>Circulation</i> , 2024, 150, 151-161.	9.3	2

#	ARTICLE	IF	CITATIONS
685	Usefulness of the P Wave Signal-Averaged Electrocardiogram in Predicting Patients at Risk of Atrial Flutter and Fibrillation Induced by Transesophageal Pacing. <i>Annals of Noninvasive Electrocardiology</i> , 1999, 4, 46-52.	1.1	1
686	Beta-Blocker Treatment Before Angiotensin-Converting Enzyme Inhibitor Therapy in Newly Diagnosed Heart Failure. <i>Journal of the American College of Cardiology</i> , 2005, 46, 182.	5.6	1
687	Intravenous Iron Sucrose in Anemic and Non-anemic Iron Deficient Patients with CHF: A Randomized, Controlled, Observer-blinded Intervention Study (FERRIC-HF). <i>Journal of Cardiac Failure</i> , 2006, 12, S179.	1.7	1
688	Response to Letter Regarding Article, "Anabolic Deficiency in Men With Chronic Heart Failure: Prevalence and Detrimental Impact on Survival". <i>Circulation</i> , 2007, 115, .	9.3	1
689	Time to Treatment and Vasodilator Efficacy in Acute Heart Failure: Results from the Pre-RELAX-AHF Study. <i>Journal of Cardiac Failure</i> , 2009, 15, S68.	1.7	1
690	Anticoagulación para pacientes con insuficiencia cardiaca en ritmo sinusal: habitual en la práctica clínica, pero aún no basada en la evidencia. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 687-689.	1.4	1
691	Central Sleep Apnea in Heart Failure Worsens Throughout the Night. <i>Chest</i> , 2015, 148, 1047A.	0.9	1
692	Non-invasive approach for the assessment of sympathetic baroreflex function: A feasibility study. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2017, 203, 108-112.	2.7	1
693	Phrenic Nerve Stimulation for Central Sleep Apnea is Effective and Safe in the Presence of Concomitant Cardiac Devices. <i>Journal of Cardiac Failure</i> , 2018, 24, S17-S18.	1.7	1
694	Pulse pressure and prognosis in patients with heart failure with reduced ejection fraction. <i>European Journal of Clinical Investigation</i> , 2019, 49, e13092.	3.4	1
695	Corrigendum to "Trimetazidine in cardiovascular medicine." [Int. J. Cardiol., 293 (2019) 39-44]. <i>International Journal of Cardiology</i> , 2020, 320, 26.	1.6	1
696	FC 021 EFFICACY OF INTRAVENOUS FERRIC CARBOXYMALTOSIDE IN PATIENTS WITH IRON DEFICIENCY FOLLOWING ACUTE HEART FAILURE, ACCORDING TO BASELINE EGFR: A SUBGROUP ANALYSIS OF THE AFFIRM-AHF TRIAL. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, .	0.8	1
697	Low ventilatory responsiveness to transient hypoxia or breath-holding predicts fast marathon performance in healthy middle-aged and older men. <i>Scientific Reports</i> , 2021, 11, 10255.	3.4	1
698	Pol-tako – the first, nationwide Polish multicenter analysis of patients with takotsubo syndrome. <i>Kardiologia Polska</i> , 2021, 79, 867-869.	0.6	1
699	Application of levosimendan in acute heart failure patients with symptoms of low cardiac output: case series report. <i>Kardiologia Polska</i> , 2013, 71, 275-278.	0.6	1
700	Valsalva-derived Measures and Phenylephrine Test in Patients With Heart Failure With Reduced Ejection Fraction Receiving Comprehensive Neurohormonal Blockade Drug Therapy: A 5-year Event-free Survival Analysis. <i>Journal of Cardiac Failure</i> , 2022, 28, 744-755.	1.7	1
701	Editorial comment on effect of exercise training in patients with heart failure. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2004, 11, 168-170.	2.8	0
702	Rationale and design of CIBIS III. <i>Country Review Ukraine</i> , 2006, 8, C35-C42.	0.9	0

#	ARTICLE	IF	CITATIONS
703	Hematinics in Patients with Complicated Acute Myocardial Infarction: Results from an OPTIMAAL Substudy. <i>Journal of Cardiac Failure</i> , 2008, 14, S34.	1.7	0
704	Prognostic Value of Mid-Regional Pro-Adrenomedullin in Patients with Chronic Heart Failure (CHF). <i>Journal of Cardiac Failure</i> , 2008, 14, S90.	1.7	0
705	Worsening Renal Function in Acute Heart Failure: Change in Blood Pressure and Effects of Relaxin. <i>Journal of Cardiac Failure</i> , 2009, 15, S63.	1.7	0
706	Troponin Release in Patients Admitted with Acute Decompensated Heart Failure and Renal Dysfunction: Results from the Pilot Phase of the PROTECT Trial. <i>Journal of Cardiac Failure</i> , 2009, 15, S36-S37.	1.7	0
707	Guía de práctica clínica para la valoración del riesgo cardiaco preoperatorio y el manejo cardiaco perioperatorio en la cirugía no cardíaca. <i>Revista Española De Cardiología (English Ed)</i> , 2009, 62, 1467.e1-1467.e56.	0.7	0
708	Treating in-stent restenosis with drug-eluting balloon with intracoronary ultrasound control, with later optical coherent tomography control. <i>Postepy W Kardiologii Interwencyjnej</i> , 2010, 4, 203-207.	0.2	0
709	Single Night Transvenous Phrenic Nerve Stimulation Improves Central Sleep Apnoea In Systolic Heart Failure. , 2011, , .		0
710	Anticoagulation for Heart Failure Patients in Sinus Rhythm: Common in Clinical Practice But Still Not Evidence-based. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2012, 65, 687-689.	0.7	0
711	Phrenic Nerve Stimulation Improves Circulatory Delay in Patients With Heart Failure and Central Sleep Apnea. <i>Journal of Cardiac Failure</i> , 2012, 18, S14-S15.	1.7	0
712	CoreValve transcatheter aortic valve implantation complicated by stress cardiomyopathy (tako-tsubo) and septic shock. <i>Postepy W Kardiologii Interwencyjnej</i> , 2012, 4, 335-337.	0.2	0
713	Coronary rotational atherectomy in patients with unsuccessful classical angioplasty “ in-hospital and six-month follow-up. <i>Postepy W Kardiologii Interwencyjnej</i> , 2012, 2, 85-90.	0.2	0
714	Management of Chronic Heart Failure “ Update 2013. <i>Journal of Cardiac Failure</i> , 2013, 19, S109.	1.7	0
715	Percutaneous reduction of mitral valve regurgitation using the MitraClip system “ immediate and 90-day follow-up of 3 cases. <i>Postepy W Kardiologii Interwencyjnej</i> , 2013, 2, 126-131.	0.2	0
716	Design and Rationale of the Soluble Guanylate Cyclase Stimulator in Heart Failure Studies (SOCRATES). <i>Journal of Cardiac Failure</i> , 2014, 20, S39.	1.7	0
717	Considerable Regional Variation in AAV1 Neutralizing Antibodies and Its Consequences for a Multinational Clinical Trial of Gene Transfer for Advanced Heart Failure: The CUPID 2 Experience. <i>Journal of Cardiac Failure</i> , 2014, 20, S93.	1.7	0
718	Prevalence of Central Sleep Apnea in Patients Screened During the remedÅ® System Pilot Study. <i>Journal of Cardiac Failure</i> , 2014, 20, S117-S118.	1.7	0
719	Prediction of Post-Discharge Outcomes for Patients Hospitalized with Heart Failure: Results from PROTECT. <i>Journal of Cardiac Failure</i> , 2015, 21, S64.	1.7	0
720	Late Cardiac Tamponade as a Result of Parietal Pericardium Erosion. <i>Annals of Thoracic Surgery</i> , 2015, 100, 715-717.	1.4	0

#	ARTICLE	IF	CITATIONS
721	Iron Deficiency in Heart Failure. , 2016, , 535-547.		0
722	Contemporary Pharmacological Treatment of Heart Failure. , 2016, , 207-227.		0
723	Transvenous Phrenic Nerve Stimulation Effectiveness is Sustained at 18 Months: Data From the Remede System Pivotal Trial. Chest, 2017, 152, A734.	0.9	0
724	Effect of Implantable Cardioverter-Defibrillators by Etiology of Heart Failure: A Propensity-Matched Mortality Analysis of the WARCEF Trial. Journal of Cardiac Failure, 2018, 24, S75.	1.7	0
725	Association between Left Ventricular Ejection Fraction and Worsening Renal Function in Acute Heart Failure: Insights from the RELAX-AHF-2 Trial. Journal of Cardiac Failure, 2019, 25, S51.	1.7	0
726	Re: Pacing, takotsubo syndrome, and transient rise of pacing threshold: What is the mechanism?. PACE - Pacing and Clinical Electrophysiology, 2020, 43, 772-773.	1.2	0
727	The short-term benefit from nurse-led ambulatory care supported by non-invasive haemodynamic assessment in patients after acute heart failure decompensation depends on time since hospital discharge. Kardiologia Polska, 2021, 79, 855-857.	0.6	0
728	Iron deficiency in patients with chronic kidney disease requiring hemodialysis: do inflammation and overexpressed hepcidin contribute significantly?. Polish Archives of Internal Medicine, 2013, 123, 68-70.	0.4	0
729	Heart rate profile: from physiology to clinical practice. Kardiologia Polska, 2013, 71, 184-190.	0.6	0
730	Intracardiac thrombi in pulmonary embolism of a priori non high risk: therapeutic dilemma. Kardiologia Polska, 2013, 71, 399-402.	0.6	0
731	A 67-year-old men with not corrected tetralogy of Fallot. Kardiologia Polska, 2013, 71, 861-863.	0.6	0
732	P-R interval in porcine model of chronic tachycardia-induced cardiomyopathy. Bulletin of the Veterinary Institute in Pulawy = Biuletyn Instytutu Weterynarii W Pulawach, 2013, 57, 437-441.	0.4	0
733	Does right ventricular pacing increase the risk of ventricular arrhythmias in patients with an implantable cardioverter-defibrillator?. Kardiologia Polska, 2014, 72, 381-384.	0.6	0
734	Increase in heart failure mortality in Poland: can we explain the reasons?. Polish Archives of Internal Medicine, 2014, 124, 274-275.	0.4	0
735	Attitude towards knowledge of the disease and psychological characteristics of patients with systolic heart failure. Health Psychology Report, 2017, 1, 30-40.	1.0	0
736	Sacubitril/valsartan for treatment of chronic heart failure with reduced ejection fraction. Can all patients benefit? A position statement paper of experts of the Heart Failure Working Group of the Polish Cardiac Society. Kardiologia Polska, 2017, 75, 286-293.	0.6	0
737	Sacubitril/valsartan for treatment of chronic heart failure with reduced ejection fraction. Can all patients benefit? A position statement paper of experts of the Heart Failure Working Group of the Polish Cardiac Society. Kardiologia Polska, 2017, 75, 33-41.	0.6	0
738	128â€ŒClinical impact of changes in mitral regurgitation severity after optimization of medical therapy in heart failure: insights from BIOSTAT-CHF. European Heart Journal Supplements, 2021, 23, .	0.1	0

#	ARTICLE	IF	CITATIONS
739	Induction of Day-Time Periodic Breathing is Associated With Augmented Reflex Response From Peripheral Chemoreceptors in Male Patients With Systolic Heart Failure. <i>Frontiers in Physiology</i> , 2022, 13, .	2.8	0
740	Pathophysiology and Treatment Opportunities of Iron Deficiency in Heart Failure: Is There a Need for Further Trials?. <i>Current Heart Failure Reports</i> , 0, , .	3.2	0
741	Evolution of NT-proBNP During Prerandomization Screening in VICTORIA: Implications for Clinical Outcomes and Efficacy of Vericiguat. <i>Circulation: Heart Failure</i> , 2023, 16, .	4.2	0
742	Intravenous iron supplementation improves energy metabolism of exercising skeletal muscles without effect on either oxidative stress or inflammation in male patients with heart failure with reduced ejection fraction. <i>Cardiology Journal</i> , 2024, 31, 300-308.	1.3	0
743	Iron Deficiency in Heart Failure: A Korea-Oriented Review. <i>International Journal of Heart Failure</i> , 2023, 5, 173.	0.0	0
744	Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER. <i>Circulation: Heart Failure</i> , 2023, 16, .	4.2	0
745	Global Rounds: Poland. <i>Circulation</i> , 2024, 149, 174-176.	9.3	0
746	Hierarchical End Points in Prior Heart Failure Trials and the HEART-FID Trial. <i>Circulation: Heart Failure</i> , 2024, 17, .	4.2	0